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NOVEL THERAPIES FOR NAFLD 
BACKGROUND/AIMS 
Non Alcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease often associated with 
metabolic disorders like type 2 diabetes, cardiovascular disease, obesity, and metabolic 
syndrome.  It is characterized by hepatic fat accumulation (steatosis) that is at or above 
5% of liver weight in the absence of excessive alcohol consumption (< 20 g/day). Current 
treatment for NAFLD focuses on reducing body weight and improving insulin action. The 
intent of this thesis was to identify therapies that targeted the liver. In the first aim, we 
examined whether secretions from plant roots contained compounds that restricted 
lipid accumulation or improved insulin action. The second aim examined whether 
taurine could prevent characteristic features of disease progression. Specifically, we 
hypothesized that (1) onion root exudates will prevent or reduce lipid accumulation and 
improve insulin signaling and (2) taurine will prevent or reduce endoplasmic reticulum 








To examine these hypotheses, liver cells and dietary models of NAFLD were employed. 
Analyses focused on hepatic triglycerides, insulin signaling, ER stress, oxidative stress 
and inflammation using basic biochemical methods such as western blotting, Real Time 
PCR, immunohistochemistry and enzyme-linked assays.  
 
RESULTS 
Onion root exudates prevented fatty acid-mediated lipid accumulation and 
enhanced insulin signaling in H4IIE liver cells.  Onion root exudates reduced plasma 
glucose, free fatty acids (FFA), and improved insulin action in rats fed a high fat diet.  
Taurine mitigated palmitate-mediated caspase-3 activity, cell death, ER stress, 
and oxidative stress in H4IIE liver cells and primary hepatocytes. In rats fed a high 
sucrose diet, taurine supplementation significantly reduced hepatic lipid accumulation, 
liver injury, inflammation, plasma triglycerides and insulin levels. The high sucrose diet 
resulted in an induction of multiple components of the unfolded protein response (UPR) 
in the liver consistent with ER stress which was ameliorated by taurine 
supplementation. Treatment of mice with the ER stress inducing agent tunicamycin 
resulted in liver injury, UPR induction and hepatic lipid accumulation, and this was 
significantly ameliorated by supplementation with taurine. 
 
CONCLUSION 
Both onion root exudates and taurine reduced metabolic abnormalities 




lipid accumulation and enhanced insulin sensitivity in the liver, while taurine reduced 
hepatic steatosis, ER stress, oxidative stress and liver injury.  Overall, onion root 
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Non Alcoholic Fatty Liver Disease (NAFLD) is an emerging disease associated with 
metabolic dysfunction.  NAFLD ranges from simple steatosis, or steatosis accompanied 
by inflammation and fibrosis (steatohepatitis or NASH) that can further develop into 
cirrhosis or hepatocellular carcinoma (HCC).  The progression of simple steatosis to 
NASH is thought to occur via the “two-hit hypothesis”;1 hepatic fat accumulation acts as 
a predisposing factor (1st hit) to further insults (2nd hits) such as oxidative stress, 
cytokines, bacterial endotoxin, or endoplasmic reticulum (ER) stress.  In addition, fat 
accumulation in the liver is associated with insulin resistant states, which is a common 
feature among individuals with obesity, type 2 diabetes, and/or metabolic syndrome.2-10  
In fact, NAFLD has been estimated to affect up to 30% of the population.  There is a 
substantial positive correlation between the rising obesity trend and  NAFLD, which has 
also been observed in obese children.2,11-15  There is no exclusive treatment for NAFLD, 
and as a result it is often treated with therapies intended for obesity and diabetes.16  
These treatments include weight loss, insulin sensitizers, lipid-lowering drugs, and/or 
antioxidants, which have a number of side effects and are not designed to treat specific 




stage features that include inflammation and fibrosis.16  Our intent is to identify 
therapies that can decrease steatosis, improve insulin action and/or ameliorate 
oxidative stress and ER stress in the liver. 
PLANT ROOT EXUDATION 
 Plant bioactive compounds can affect characteristics of NAFLD, in 
particular insulin resistance and inflammation.  As most studies have focused on 
compounds that arise from the above ground portion of plants, that which rests below 
ground is largely unstudied in the context of potential therapeutic sources.  Plant roots 
have the ability to secrete (exude) a variety of compound into their surrounding 
environment, known as the “rhizosphere”.  The composition of these “exudates” is 
dependent on temperature, age and species of the plant, biotic, and abiotic factors.17   
Plant roots exudates have a variety of purposes, from communication and/or symbiosis 
with surrounding plants and microbes, altering nutrients into forms able to be taken up 
by the plant, and allelopathy.17-19  The potency of exudates is enough to alter gene 
regulation of plants and microbes living in the surrounding rhizosphere, in some cases 
altering pathways involved in carbohydrate and lipid metabolism.20 As these pathways 
are potentially dysfunctional in NAFLD, the bioactive potential of plant root exudates is 
promising.  Preliminary studies done by our lab suggest onion root exudates contain 
bioactive compounds that can prevent lipid accumulation and enhance insulin signaling 






Taurine is a small amino sulphonic acid which can be obtained through the diet 
or synthesized endogenously from methionine and cysteine. Taurine aids in numerous 
physiological processes, including bile salt formation, osmoregulation, central nervous 
system function, and calcium homeostasis.  Taurine deficiency has been observed in 
some studies involving individuals with obesity, type 2 diabetes and cirrhosis. In the 
studies involving patients with obesity and type 2 diabetes, supplementation of taurine 
improved characteristics of these diseases, although the mechanisms by which they do 
so remain unclear.  Since NAFLD is observed in up to 80% of the cases of obesity and 
type 2 diabetes, the improvements observed with taurine treatment might involve 
pathways that also play a role in the progression of liver disease in NAFLD.  In models of 
NASH, a progressive stage of NAFLD, oxidative stress, ER stress, inflammation and liver 
injury are key characteristics observed along with hepatic steatosis and insulin 
resistance.   Increasing evidence suggests that taurine may have beneficial effects on 
NAFLD.21  Taurine supplementation prevents alcoholic fatty liver disease in experimental 
animals, and mice characterized by hetero- or homozygous knockout of the taurine 
transporter develop chronic liver disease characterized by fibrosis, inflammation and 
hepatocyte apoptosis.22,23  Interestingly, the beneficial effects of taurine are often 
accompanied by reductions in ER stress, suggesting a link between the therapeutic 
properties of taurine and restoration of ER homeostasis.24-26  The above studies give 
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Metabolic disorders related to excess nutrient intake have been on the rise in 
recent decades.  Increased incidences of metabolic syndrome, obesity and type 2 
diabetes have also lead to an increased awareness of the significance of comorbidities 
associated with these diseases, one of which is nonalcoholic fatty liver disease (NAFLD).  
NAFLD is a metabolic-related disorder characterized by fat infiltration of the liver in the 
absence of chronic alcohol consumption.  Clinically, NAFLD encompasses a broad 
spectrum of hepatic derangements ranging from fat accumulation (steatosis) to severe 
inflammation and fibrosis (NASH, nonalcoholic steatohepatitis) that can lead to cirrhosis 
(Figure 1).  Recent estimates suggest that up to 30% of the general population have 
some form of NAFLD and up to 75% of patients with obesity and diabetes mellitus have 
NAFLD.  The increasing prevalence of NAFLD in children has made it a common pediatric 
disease, affecting 3-9% of all children and up to 50% of obese children.1 Approximately 
90% of patients with NAFLD have at least one characteristic of the metabolic syndrome, 
which is characterized by a patient having any three of the following: abdominal obesity 




35 inches), triglyceride levels greater than 150 mg/dl, HDL concentrations less than 40 
mg/dl in men and 50 mg/dl in women, blood pressure >130/>85 mmHg, and fasting 
glucose levels greater than 110 mg/dl.2,3  More recent studies have indicated that 
NAFLD is associated with an increased risk of cardiovascular disease.4   
 
Figure 1. Progression of NAFLD.  Fat accumulation (steatosis) occurs as a consequence of 
either increased import of triglyceride into hepatocytes or decreased export of 
triglyceride from hepatocytes. Steatosis predisposes the liver to susceptibility to a 
second “hit” trigger that can lead to inflammation, fibrosis, and hepatocellular injury 
characterized by NASH.  If NASH further progresses, it can develop into cirrhosis of the 
liver. 
ETIOLOGY OF NAFLD 
 The initial stage of NAFLD involves accumulation of triglycerides (TG) in 
the liver. Hepatic lipids are derived from three potential sources: the diet, de novo 
lipogenesis (DNL) and circulating fatty acids released from adipose tissue (Figure 2).5 A 




nonesterified fatty acids (NEFA), dietary fatty acids, and those derived from DNL  in 
adult humans with NAFLD over a 4 day period.6 NEFAs contributed 59.0%±9.9%, DNL 
contributed 26.1%±6.7% and diet contributed 14.9%±7.0% to the triacylglycerol present 
in the liver.6  Studies performed using animal models generally support the role of diet, 
lipogenesis and circulating NEFA in the development of hepatic steatosis. For example, 
Larter et al. fed a high fat diet to mice genetically predisposed to obesity and diabetes 
and demonstrated that dietary lipid was partitioned to the liver, diabetes was induced 
and adiponectin secretion reduced.7  These events preceded the development of 
steatohepatitis and fibrosis in these mice.7   DNL involves the conversion of 
carbohydrate-derived acetyl coenzyme A to fatty acid.  Once synthesized, these fatty 
acids can be incorporated into triglyceride and stored in or released by the liver.  
Normally in the fasted state, the contribution of DNL to the hepatic triglyceride pool is 
very small; however it appears to be elevated in insulin resistant states and in NAFLD.8,9  
Hepatic overexpression of diacylglycerol acyltransferase (DGAT2, the final committed 
step in triglyceride synthesis) promotes hepatic steatosis in mice, however this steatosis 
was insufficient to cause insulin resistance.10  The implications of this study are twofold; 
first, upregulation of critical proteins involved in lipid synthesis may contribute to the 
development of hepatic steatosis, and second, hepatic steatosis can occur in the 
absence of insulin resistance, and thus may be an early event in NAFLD. Although 
inhibition of DGAT2 reduced hepatic steatosis in mice with diet-induced NASH, these 
mice were characterized by exacerbation of liver damage and fibrosis.11  Finally, 




hepatic steatosis and liver damage in both human populations and animal models.12 
Thus, impairments in any of the three pathways that contribute to the input of lipid to 
the liver can contribute to the development of hepatic steatosis.  
 
The liver can also dispose of lipids via oxidation or release as very low density 
lipoprotein (VLDL) triglyceride (Figure 2).  Acetyl CoA carboxylase (ACC) is a lipogenic 
enzyme that catalyzes the synthesis of malonyl CoA, an allosteric inhibitor of carnitine 
palmitoyltransferase 1 (CPT1).  CPT1 regulates the transfer of long chain acyl-CoAs from 
the cytosol into the mitochondria for oxidation. Savage et al. demonstrated that 
suppression of ACC1 and 2 reversed both diet-induced hepatic steatosis and hepatic 
insulin resistance in rats via mechanisms that involved enhanced hepatic fat oxidation in 
the fed state.13 Minehira et al. demonstrated that inhibition of VLDL secretion, through 
hepatic deletion of microsomal triglyceride transfer protein (MTTP), resulted in hepatic 
steatosis in the absence of changes in peripheral lipid stores and insulin sensitivity in 
mice.14  Therefore, imbalances in lipid input relative to output can also promote hepatic 
steatosis. 
 
The accumulation of lipids, in particular lipids characterized by increased 
saturated fatty acids, can be toxic to cells, a condition termed lipotoxicity. Lipotoxicity is 
not a result of triglyceride accumulation itself, but rather the lipid-derived metabolites 
that can activate inflammatory and ROS generating pathways.15 Saturated fatty acids 




in human and rat hepatocytes.16-18  Unsaturated fatty acids such as oleate exhibit a 
protective role against palmitate-induced apoptosis by promoting palmitate 
incorporation into triglyceride rather than into pro-apoptotic pathways.19 In the event 
that triglyceride accumulation is impaired or exhausted, free fatty acids may no longer 
be safely incorporated into triglyceride pools and instead act to increase susceptibility to 
liver injury and second hit triggers leading to NASH development.  
 
Figure 2. Input and output pathways of lipid to and from the liver.  Lipids can enter the 
liver either through diet, FFA, or lipogenesis.  Once inside the liver, lipids can be 
esterified with glycerol into TG, while lipogenesis involves the conversion of precursors 
like glucose to FFA, where they are esterified with glycerol to produce TG. Liver TG can 
be broken down to FFA and exported via mitochondrial oxidation, or packaged into 
VLDL for export to various other tissues. In a normal liver, this TG flux is in balance so 
the net amount of TG stored in the liver is very low, however in states of nutrient excess 





CONSEQUENCES OF HEPATIC STEATOSIS 
Lipid accumulation in insulin sensitive tissues has been linked to insulin 
resistance in both human and animal studies.20-23  Thus one potential consequence of 
hepatic steatosis is the development of insulin resistance.  Samuel et al., using a short 
term, high fat diet in rats, demonstrated that hepatic fat accumulation was followed by 
hepatic insulin resistance.24 In this study, hepatic fat accumulation decreased insulin 
activation of glycogen synthase and increased gluconeogenesis. 24  These changes were 
associated with activation of proteins, protein kinase C-e and c-Jun terminal kinase, 
which interfere with tyrosine phosphorylation of IRS-1 and IRS-2 and therefore insulin 
signaling.24  Several studies have demonstrated that hepatic steatosis is more closely 
linked to hepatic insulin resistance than factors such as whole body obesity, visceral 
obesity or circulating fatty acids in humans. 21,25-28 
 
Fat accumulation in the liver leads to a variety of consequences, namely systemic 
insulin resistance and impaired insulin extraction by the liver.  Hwang et al. sought to 
elucidate what lipid depot (i.e. intramyocellular lipid (IMCL), intrahepatic triglyceride 
(IHTG), visceral fat (VF), and/or deep abdominal subcutateous fat (SF)) was correlated 
with insulin resistance.25  Using 1H-magnetic resonance spectroscopy and magnetic 
resonance imaging, they were able to show significant inverse correlation between IHTG 
and whole body Rd.25  This correlation suggests hepatic triglyceride accumulation can 
have systemic consequences involving impaired insulin sensitivity in non-hepatic tissues.  




diabetic subjects, 50-70% of the insulin secreted by the pancreas is removed by the liver 
during first-pass transit.29-36 In advanced liver disease, hepatic insulin clearance is 
reduced, which is considered to be a major cause of hyperinsulinemia in liver 
cirrhosis.37-40 Recent work by Kotronen et al has demonstrated that increased liver fat is 
associated with impaired insulin clearance in nondiabetic human subjects.29 Thus, it is 
possible that the link between liver fat and non-hepatic insulin resistance involved a 
sequence of events that include reduced hepatic insulin clearance, increased systemic 
insulin concentrations, and down regulation of insulin receptors and insulin signaling. 
TRIGGERS INDUCING NASH DEVELOPMENT 
NASH is characterized by steatosis and the induction of inflammation, fibrosis, 
and hepatocellular injury. It is interesting that not all of individuals with hepatic 
steatosis develop NASH. It has been estimated that 15-25% of cases of early stage 
NAFLD progress to NASH, and 15-20% of NASH cases further develop into cirrhosis.41 As 
a result of this data, it has been suggested that steatosis increases susceptibility of the 
liver to various other triggers, and those individuals characterized by the appropriate 
combination of triggers will be at highest risk for development of NASH (Figure 3).    This 
concept has experimental support. In a study by Zhang et al., mice were fed a high fat 
diet (60% daily caloric intake) for 8 months to induce steatosis, obesity, insulin 
resistance and dyslipidemia.42  There was no evidence of significant liver damage or 
inflammation produced by the diet.42  Hepatocytes were then isolated; steatotic 
hepatocytes had increased production of intracellular ROS and were more susceptible to 




that a combination of steatosis and triggers such as increased cytokines may promote 
the development of NASH. 
 
Figure 3. Types of triggers in the progression of NAFLD.  Steatosis predisposes the liver 
to injury from 2nd hit triggers, which can include oxidative stress, cytokines, bacterial 
endotoxin, or ER stress.   
Several so-called second “hit” triggers, in addition to cytokines, have been 
proposed including oxidative stress, bacterial endotoxin, and/or ER stress (Figure 3). 
While simple steatosis occurs primarily in hepatocytes, the development of 
inflammation and fibrosis (characteristic features of NASH) involve Kupffer cells and 
stellate cells, respectively (Figure 4). Thus, the development of NASH is much more 
complex than the development of steatosis and involves multiple triggers and cell types 





Figure 4. Liver cell types involved in the progression of NAFLD.  Lipid accumulation 
occurs primarily in hepatocytes, while inflammation occurs as a result of cytokine 
release from kupffer cells and adipose tissue.  Inflammation leads to hepatic stellate cell 
activation and the induction of fibrosis. 
OXIDATIVE STRESS 
Oxidative stress occurs when reactive oxygen species (ROS) are produced in 
excess of antioxidant defenses.43-44  ROS is a collective term that includes both oxygen 
radicals such as singlet oxygen and the superoxide anion, and certain nonradicals that 
are oxidizing agents and/or are easily converted into radicals, such as hydrogen peroxide 




metabolism and can cause damage leading to cell death.  In the liver, oxidative stress 
can be generated through mechanisms involving mitochondrial dysfunction (leading to 
progressive impairment of b-oxidation, respiratory chain, and ATP synthesis), increased 
fatty acid oxidation in either peroxisomes (β-oxidation) by acyl-CoA oxidase or in the 
endoplasmic reticulum by CYP-2E1 and CYP4A isoforms or ER protein folding.44,46  
MITOCHONDRIA 
FFA oxidation in mitochondria involves electron generation through redox 
reactions of the cofactors NAD+ and FAD to/from NADH and FADH2.
47,48  These electrons 
are transferred to the electron transport chain where they generate an electrochemical 
potential required for oxidative phosphorylation and the generation of ATP.47,48  
Normally electrons travel through the electron transport chain to cytochrome C oxidase, 
where they combine with oxygen and protons to form water.47,48  Sometimes, a fraction 
of these electrons “leak” from the electron transport chain and react directly with 
oxygen to form the ROS superoxide.47,48  Manganese superoxide dismutase (Mn-SOD) 
converts superoxide into peroxide, which is further converted to water by mitochondrial 
glutathione peroxidase (which requires reduced glutathione to function).49,50  A 
dysfunctional mitochondrial environment where either the endogenous antioxidant 
enzymes Mn-SOD or glutathione peroxidase are downregulated or lacking in substrate 
to function properly promotes ROS formation.50-52 Ectopic expression of cytochrome 





Mitochondrial structure can also play a role in its dysfunction; in NASH patients, 
at least 40% of mitochondria are structurally abnormal.60  These abnormalities (enlarged 
mitochondria, loss of mitochondrial cristae and paracrystalline inclusions) impair the 
electron transport chain enzyme activity and lead to uncoupling of oxidation from 
phosphorylation and production of ROS.50,61,62 Enhanced mitochondrial ROS formation 
has been shown in obese mice and hepatocyte and rat models of obesity and 
NASH.53,63,64 NASH patients have been reported to have enhanced hepatic levels of 
CYP2E1; studies in streptozotocin-induced diabetic rats showed increased levels and 
activity of mitochondrial CYP2E1 in the livers and other tissues, providing another 
potential source of ROS.53 
PEROXISOMES/MICROSOMES 
Fatty acid β-oxidation or ω-oxidation can also occur in peroxisomes and 
microsomes, respectively; however, hydrogen peroxide is generated without the 
coupling of oxidative phosphorylation.65-68  The endogenous antioxidant enzyme of 
peroxisomes is catalase, which converts hydrogen peroxide to water.  If the amount or 
activity of catalase is insufficient to reduce the hydrogen peroxide produced through β-
oxidation, the hydrogen peroxide can react with cell components, particularly lipids, and 
causing cell damage and death.65-68  As peroxisomal FFA β-oxidation is viewed as a 
protective response to fatty acid overload in the liver mediated by PPAR-α, recent 
studies have shown PPAR-α expression in NAFLD patients is reduced.69-74  Gene 
expression studies in NAFLD patients show enhanced expression of DNL, fatty acid 




indicating antioxidant gene expression was adjusted to deal with the excess ROS 
generated from fatty acid oxidation.72  A study done in sodium valproate induced 
steatotic rats showed that, in addition to structural and functional alterations in hepatic 
mitochondria, increased lipid peroxidation was evident in hepatic peroxisomes and 
microsomes when compared to nonsteatotic control rats.75  These studies suggest there 
are impairments in fatty acid oxidation that generates ROS in NAFLD livers, making them 
more susceptible to lipotoxic conditions. 
ENDOPLASMIC RETICULUM 
The endoplasmic reticulum (ER) is an organelle responsible for many cell 
processes, including oxidative processes like protein folding that can generate ROS.  
Protein folding is an essential function of the ER mediated by protein disulphide 
isomerases (PDI), FAD dependent oxidases ERO1p, ERV2p and Fmo1p, with the final 
electron transfer being from ERO1p to 02 with peroxide and superoxide as minor 
electron acceptors from ERO1p.76  Uncoupling of ERO1p, e.g. during ER stress 
(disruption of ER function leading to complex signaling cascades that attempt to 
ameliorate the stress), can lead to generation of ROS.76   
 
The cytochrome P450 family of proteins are a diverse group of enzymes, most of 
which are involved in catalyzing the oxidation of organic substances such as lipids, 
steroids, and xenobiotics.  Two cytochrome P450 enzymes, CYP2E1 and CYP4A, are 
found in the ER and are responsible for a variety of detoxification reactions.  CYP2E1 




and ω-1 hydroxylation of medium chain fatty acids (C6-C12).
77 CYP2E1 catalyzes the 
NADH-dependent reduction of oxygen leading to lipid peroxidation.78,79 CYP2E1 
expression has been shown to be increased in both rat dietary models of steatohepatitis 
as well as in the livers of patients with NASH.78,80  In mice fed an methionine choline 
deficient diet (MCD diet), steatohepatitis was induced as well as CYP2E1 expression and 
catalysis of lipid peroxides by hepatic microsomes.78  This study showed that CYP2E1 can 
act as an initiator of oxidative stress in steatotic livers, however when CYP2E1 knockout 
mice were fed a MCD diet, steatohepatitis and lipid peroxidation were still induced, 
suggesting there are other catalysts to lipid peroxidation involved in the progression of 
steatohepatitis.78  One such alternative catalyst is CYP4A, which was discovered in vitro 
to play a role in lipid peroxidation in the absence of CYP2E1.78 Thus targeting a specific 
enzyme involved in lipid peroxidation may be futile due to the redundant nature of 
microsomal enzyme expression in lipid store management under conditions of NAFLD. 
 
Oxidative stress can induce other forms of stress that further propagate the 
progression of NAFLD.  Hanada et al. used human hepatoma cells and hepatocytes to 
show that oxidative stress coupled with limited proteosome inhibition induced ER 
dysfunction and inclusion formation.81 Inclusion formations (or Mallory bodies) in 
hepatocytes are significant markers of many liver diseases, including NASH.  Prevention 
or alleviation of oxidative stress may prevent or reduce Mallory body formation and ER 





Cytokines are pleiotropic regulatory peptides that can be made by virtually all 
nucleated cells in the body.82  Types of cytokines include interferons, interleukins (IL), 
tumor necrosis factors (TNF), colony stimulating factors (CSF), transforming growth 
factors (TGF), erythropoietin, and thymopoietin.  When the immune system is activated, 
cytokines activate and signal immune cells such as T-cells and macrophages to travel to 
the site of infection.  Activated immune cells also release cytokines, propagating the 
immune response signal.  Cytokines can be either pro-inflammatory (i.e. tumor necrosis 
factor-  (TNF- ), interleukin-1 (IL-1), interleukin-6 (IL-6)) or anti-inflammatory (i.e. IL-1 
receptor antagonist, interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-13 (IL-13)).  
Pro-inflammatory cytokines can upregulate the synthesis of secondary mediators and 
pro-inflammatory cytokines by macrophages and mesenchymal cells, stimulate 
production of acute phase proteins, attract inflammatory cells, or act as endogenous 
pyrogens (elevate thermoregulatory setpoint of the hypothalamus).  Anti-inflammatory 
cytokines counteract inflammation through direct inhibition of pro-inflammatory 
cytokines or through other means.  In the context of liver injury, TNF-a production 
occurs early and triggers production of other cytokines that recruit inflammatory cells, 
kill hepatocytes, and initiate fibrogenesis.83 
 
The liver plays a secretory role in the development of NASH in the context of 
cytokine release from Kupffer cells (resident hepatic macrophages).84 TNF-a production 




kill hepatocytes, and initiate fibrogenesis.  From a positional standpoint, both the liver 
and visceral adipose tissue share proximal associations between metabolic cells 
(hepatocytes and adipocytes, respectively) and secretory cells such as immune cells (NK 
and NKT cells), Kupffer cells, hepatic stellate cells, endothelial cells or macrophages, 
with each tissue having immediate access to an extensive network of blood vessels for 
continuous or dynamic immune and metabolic responses.84,85 Data in the fatty livers of 
Zucker diabetic (fa/fa) rats and leptin deficient ob/ob mice showed abnormal basal 
cytokine production and/or after a Kupffer cell-activating LPS challenge, which resulted 
in the development of severe NASH.86,87 The significance of these studies was that a 
cytokine (TNF , released by many types of cells but predominately Kupffer cells in the 
context of LPS-induced lipotoxicity) was shown to be dysfunctionally released in 
conditions of hepatic steatosis and contributed to the severity of NASH.  TNF  has 
consistently shown to be increased in patients with NASH, and correlates with NASH 
severity.88,89 
 
A subcategory of cytokines specific (but not exclusive) to adipose tissue is 
termed adipokines. White adipose tissue serves three known functions, energy storage, 
hydrolysis of triglyceride to free fatty acids, and release of adipokines, since adipose 
tissue contains adipokine-producing cells such as macrophages, fibroblasts and 
infiltrating monocytes.90  In the context of NAFLD, obesity contributes to a higher 
prevalence of cirrhosis, suggesting that adipose tissue is a significant factor in the 




 Visceral adipose tissue seems to play an important role in the 
development of NASH by secreting FFA, hormones and adipokines.84 Visceral adipose 
tissue, like the liver, shares proximal associations between metabolic cells (adipocytes) 
and secretory cells such as immune cells (NK and NKT cells), endothelial cells or 
macrophages; interspersed networking of blood vessels allows for expedited immune 
and metabolic responses.84,85 Different adipokines are expressed in subcutaneous versus 
visceral adipose tissue.  Subcutaneous adipose tissue predominantly expresses leptin, 
adiponectin, retinol binding protein-4 (RBP-4), and acylation stimulating protein, which 
are all involved in metabolic control.92  Visceral adipose tissue predominantly expresses  
inflammatory proteins, such as tumor necrosis factor-  (TNF- ), interleukin-6, 
interleukin-8, adipsin, and resistin; proteins involved in  tissue repair such as  
plasminogen activator inhibitor-1 and angiotensinogen, and proteins involved in 
regulation of metabolism, such as visfatin.84,93 Ectopic fat, such as  visceral adipose or  
epicardial or mediastinal adipose tissue of the heart, is more closely linked to 
impairments in metabolic control  and inflammation in obesity-related disorders.94 In 
NAFLD, adiponectin is inversely correlated with hepatic fat content.92,95-98 RBP-4 appears 
to be positively correlated with peripheral insulin resistance and hepatic fat content; 
however, since RBP-4 is produced by both the liver and adipose tissue, it is unclear 






Bacterial endotoxin, such as lipopolysaccharides (LPS) derived from gram-
negative bacteria, are glycolipids that have the ability to induce an inflammatory 
response in infected organisms.  The liver functions to restrict the entry of LPS from the 
GI tract into the systemic circulation. The activation of Kupffer cells in the liver plays a 
critical role in the hepatic clearance of LPS. Specifically, this activation is mediated 
through LPS binding protein (LBP), CD14, and Toll-like receptor-4 (TLR-4).  LPS binds to 
LBP in the serum, which transfers LPS to the peripheral monocyte membrane bound 
CD14. In Kupffer cells, CD14 expression is relatively low normally but is rapidly 
upregulated upon exposure to agents such as LPS. TLR-4 is a downstream component of 
CD14 and required for Kupffer cell activation.  Upon activation, Kupffer cells release 
cytokines such as TNF-a, IL-1, and reactive oxygen species (ROS).101  This inflammatory 
response can induce liver injury, perhaps not via a single cytokine alone but rather 
through disruption of the balance between pro and anti-inflammatory factors.102 
 
The composition of gut microflora can have a profound impact on caloric intake 
in both mice and humans.103-105  There are two predominant populations of microbiota 
in both the mouse and human, Firmicutes and Bacteroidetes.   In obese individuals, the 
proportion of Firmicutes is higher than that of lean individuals.104,105  The significance of 
this observation lies in the ability of Firmicutes to encode enzymes that can break down 
otherwise indigestible dietary polysaccharides, thus increasing caloric absorption.  




Alterations in the composition of gut microflora can influence the integrity of the 
liver.  In one study, Sprague-Dawley rats received either saline, probiotics, Escherichia 
coli, Salmonella enteritidis, or gentamicin orally for 7 days.107  On the 8th day, acute liver 
damage was induced by intraperitoneal injection of D-galactosamine in all but the 
control saline group.107  The probiotic, E. coli and gentamicin groups had attenuated 
liver damage, decreased bacterial translocation, and decreased levels of TNF-a, IL-6, IL-
10, and IL-12.107  Overall, the study showed that alterations in gut microflora acted 
through modifications of bacterial translocation, local gut cytokine expression, and 
endotoxin to prevent (e.g.  probiotic, E. coli and gentimicin) or exacerbate (e.g. S. 
enteritidis) acute liver injury.107  The composition of gut microbiota can also influence 
gut permeability.108  In a study done by Cani et al., ob/ob mice were treated with a 
control diet or a control diet fortified with either prebiotic or nonprebiotic 
carbohydrates.108  Prebiotic treatment involved incorporation of fermentable dietary 
fiber (oligofructose), whereas nonprebiotic treatment involved incorporation of 
nonfermentable dietary fiber (cellulose).  Prebiotic treated mice exhibited lower 
circulating LPS, cytokines, and decreased hepatic expression of inflammatory and 
oxidative stress biomarkers when compare to nonprebiotic controls.108   
ER STRESS 
The endoplamic reticulum (ER) is one of the largest cellular organelles and is  
responsible for a variety of functions, depending on the domain of ER involved (nuclear 
envelope, smooth ER, or rough ER).109 Its functions include translocation of secretory 




and modification of proteins in the ER lumen, synthesis of phospholipids and steroids, 
detoxification, storage of calcium ions in the ER lumen and their release in the cytosol, 
and segregation of nuclear contents from the cytoplasm.110,111 In the rough ER, protein 
assembly and folding homeostasis is monitored by a series of signaling pathways 
collectively known as the unfolded protein response (UPR, Figure 5).  Stressors such as 
loss of the luminal oxidizing environment, disruption of calcium homeostasis or 
impaired N-glycosylation can disrupt protein folding and lead to protein aggregate 
accumulation in the ER lumen, termed ER stress. The UPR attempts to alleviate the 
protein folding burden on the ER through activation of pathways that can decrease 
general translation and increase proteins and enzymes involved in protein folding or 
degradation (i.e. chaparones or proteases). If this effort is unsuccessful, the UPR can 
initiate apoptosis through mitochondrial dependent or independent mechanisms.112   
 
ER stress has been implicated in a wide variety of diseases, including obesity, 
diabetes and cardiovascular disease.113,114  The involvement of ER stress in NAFLD is less 
studied; however, evidence exists that it too plays a part in the pathogenesis of this 
disease.115-123  Gregor et al. followed 11 obese men and women before and 1 year post 
gastric bypass surgery.120  ER stress markers in both subcutaneous adipose and liver 
tissue were upregulated before surgery and subsequently reduced after, suggesting a 
relationship between obesity-related ER stress and metabolic dysfunction.120 Puri et al. 
compared metabolic syndrome patients with normal liver histology to those with 




phosphorylation of eIF2a (PERK associated signaling pathway of UPR), yet there was 
failure in activation of downstream recovery pathways of the UPR (ATF4, CHOP, 
GADD34).123    Thus, in patients with NAFLD, there appears to be activation of some 
components of the UPR and perhaps impairments in others.  
 
Diet composition may play a role in the development of ER stress and 
subsequent liver injury in NAFLD.  Male Wistar rats were fed diets enriched with starch 
(STD), sucrose (HSD), polyunsaturated fat (HPUFA), or saturated fat (HSAT) for 1, 4 or 24 
weeks.124  Liver triglycerides were increased to a similar extent in HSD, HPUFA, and 
HSAT compared with STD at 4 and 24 weeks; however, saturated fatty acid content of 
triglycerides and microsomal membranes was increased in HSD and HSAT compared 
with HPUFA.124 HSD and HSAT were also characterized by hepatic ER stress that 
preceded the manifestation of liver injury.124 Importantly, increased liver injury in these 
dietary models was observed independently of differences in cytokines and insulin 
action.124 These data suggest that diet composition and perhaps the composition of 
fatty acids delivered to and stored within the liver are important determinants of ER 
homeostasis and liver cell integrity.  
 
It is important to note that ER stress can affect various cell types in the liver.  A 
study done by Yang et al. demonstrated that ER stress related decreases in hepatocyte 
CD1d, a lipid antigen presenter, contributes to natural killer T cell (NKT) dysfunction in 




for CD1d trafficking to plasma membranes; however, hepatic steatosis induces ER stress 
and prevents this trafficking from occurring and results in less CD1d on the plasma 
membrane surface.  CD1d is necessary for appropriate interaction with NKT cells, and in 
its absence, NKT cells cannot be properly activated or matured to proliferate more NKT 
cells.  The liver is the primary reservoir for NKT cells in adults, and their depletion may 
have many harmful effects including increased susceptibility to obesity-associated 





Figure 5.  UPR activation. Upon accumulation of proteins in the ER, three proximal 
signaling arms are activated: activating transcription factor 6 (ATF6), inositol requiring 
enzyme 1 (IRE1), and RNA-activated protein kinase (PKR)-like ER kinase (PERK).  ATF6, 
IRE1a (through splicing of X box-binding protein 1 (XBP1)), and PERK (through activating 
transcription factor 4 (ATF4)) can induce transcriptional activation of chaparones for 
protein folding or degradation proteins to alleviate the protein load in the ER lumen.  
PERK, through phosphorylation of eiF2a, can attenuate global translation of proteins to 





In treating NAFLD, potential targets for intervention include metabolic pathways 
that contribute to the development of hepatic steatosis and/or amelioration of second 
hit triggers like oxidative stress, ER stress, cytokines, or bacterial endotoxin. Currently, 
there is no established treatment specific to NAFLD.  Weight loss, insulin sensitizers such 
as thiazolidinediones (TZDs) and metformin, and other therapies that treat obesity and 
components of the metabolic syndrome are often prescribed since they can indirectly, 
via reductions in body weight and fat mass, attenuate hepatic steatosis and disease 
progression in NAFLD.  TZDs are thought to act through adipose tissue PPARγ to increase 
peripheral insulin sensitivity.126  Metformin acts through its activation of AMPK to 
suppress hepatic glucose production.127 Rapid weight loss (greater than 1.6 kg/week) 
can cause portal inflammation and fibrosis,128 while weight loss in general can have a 
high rate of recidivism129  and thus only be a temporary solution to NAFLD progression.  
Although some studies have shown that antidiabetic agents such as metformin and 
insulin-sensitizing thiazolidinediones may improve NAFLD, the long term effects are 
unclear,  are ineffective in advanced states of NAFLD (i.e. due to fibrosis), cause weight 
gain, or are potentially hepatotoxic in some patients.130,131  Historically, plants have 
been used to prevent or treat many diseases.  Diabetes, both insulin dependent and 
independent, has been recognized and treated with medicinal plants by Chinese and 
Ayurvedic physicians for millennia.132 In fact, over 1000 species of plants have been 
reported to have been used to treat diabetes or have antidiabetic activity.133-135 A study 




from the Chinese vine Pueraria lobata, could reverse chemical-induced liver fibrosis.136  
Elevated liver enzymes, a plasma marker of liver injury,  were decreased with puerarin 
treatment, while apoptosis of activated hepatic stellate cells  was increased.136 Bcl-2 (an 
inhibitor of apoptosis) mRNA was also downregulated with puerarin.136 
Immunohistochemical staining showed a decrease in pathological characteristics of 
fibrosis (marked fatty degeneration, portal inflammation and necrosis, collagen 
deposition, hepatocyte loosening, perihepatocyte fibrosis, and slight confluence).136  
Thus, medicinal plants may provide a novel source of bioactive compounds that may be 
effective in the treatment of NAFLD. 
ONION 
Onions are a staple annual crop grown across the country, particularly in 
Colorado.  Dry storage onions make up 47% of the vegetable crops grown in Colorado, 
representing a 43 million dollar value annually.137  In addition to its agricultural 
importance, onions have been used medicinally for centuries.138 In a study done by 
Gabler et al., pigs were fed a high fat diet (25% w/w) for 2 weeks followed by 
supplementation of a low dose of onion (human equivalent to half an onion/day), a high 
dose (human equivalent of 1.5 onions/day), or no supplementation.139  Onion 
supplementation, regardless of dosage, provided a reduction in postprandial plasma 
triglycerides by 15%, antioxidant protection against lipoprotein oxidation, immune 
stimulation, and haematological responses.139  Although there was no statistical effect 
on the plasma cholesterol profile, previous studies done by the authors on different 




compounds and flavonoids have a dose dependent effect on the lipoprotein 
profile.139,140  Numerous studies have reported hypolipidemic and hypoglycemic effects 
of onions or onion extracts in diabetic rats,141 rabbits,142 and humans.143,144  Kumari et 
al. showed that the S-methyl cysteine sulfoxide (SMCS) extract of onion contributed to 
reductions in serum and tissue cholesterol, triglyceride, and phospholipids in high 
cholesterol (1%) fed rats.145  Also, adipose tissue lipoprotein lipase was downregulated, 
leading to a decrease in circulating free fatty acids.145  Overall, SMCS caused a decrease 
in endogenous lipogenesis as well as an increase in lipid catabolism and excretion.145  
SMCS also has a stimulatory effect on insulin secretion by the pancreas.146  The above 
studies illustrate that onion contains a variety of bioactive compounds, such as organo-
sulfur compounds like SMCS, which may have ameliorating effects on the 
hyperlipidemic, pro-oxidant, insulin resistant features of NAFLD. The problem with using 
onions therapeutically is that, from a dietary standpoint, a patient would have to 
consume 0.5 to 1.5 raw onions per day in order to show the effects observed in the pig 
study by Gabler et al.  Extracting compounds like SMCS may be therapeutically 
beneficial, however there may be other bioactive compounds left behind or destroyed 
during the extraction process that could have beneficial effects on patients with 
metabolic disorders.   
PLANT ROOT EXUDATION AS A SOURCE OF THERAPEUTIC COMPOUNDS 
Most bioactivity studies done on plants have focused on the part of the plant 
above the ground, thus allowing the plant root to go unnoticed. Plant roots provide 




notably, they can synthesize, accumulate, and secrete a wide range of compounds.  
Root branching and root system architecture (RSA), type of root cell (e.g. root cap, 
epidermal cells and root hairs), nutrient availability, age of plant, species of plant and 
the surrounding biotic and abiotic environment can all contribute to the specificity, 
quality, and quantity of compounds exuded by the root into the surrounding 
rhizosphere.147,148 Organic compounds such as mucilage, polysaccharides, proteins, 
organic acids, amino acids, simple sugars and secondary metabolites are the major 
components of root exudation.149 Three pathways are thought to passively mediate 
plant root exudation: diffusion, ion channels, and vesicle transport.148 More recently, 
active transport of root exudates has been shown to occur through root-specific ABC 
transporters (ATP dependent; e.g. fatty acids, flavonoids).148,150-152 
 
While diurnal variations in metabolites are commonplace among plants, a recent 
study in Arabidopsis revealed root exudation of phytochemicals was predominantly not 
influenced by diurnal rhythms.151 A study done on root exudates from  ginseng found 
that nitrogen and potassium deficiency caused enhanced exudation of a variety of 
organic and phenolic acids.153  Soil microorganisms also have the ability to influence the 
type of chemical exuded by the plant root; microbial products from the soil 
microorganisms Pseudomonas bacteria and Fusarium fungi enhanced amino acid efflux 
from the roots of alfalfa, maize, and wheat.154 Through secretion (or exudation) of 
compounds into the surrounding soil (rhizosphere), roots can regulate the surrounding 




chemical composition of the soil.155  The exudates produced by plants may be contained 
within the plant, or be unique to the root cells.  To date, there are no studies published 
pertaining to the therapeutic effect of plant root exudates on human metabolic 
diseases. A study done by Bao et al. analyzed the effect of pretreatment of the turmeric 
rhizome (the underground stem of a plant where roots and shoots originate) derived 
bioactive constituent curcumin on oxidative stress induced by ethanol in hepatocytes.156  
Curcumin pretreatment alleviated hepatocyte damage through redox enzyme regulation 
and through a dose and time dependent induction of heme oxygenase-1, which is the 
rate limiting enzyme in the breakdown of heme into carbon monoxide, iron, and 
bilirubin.156  Another study demonstrated that rhizome extracts of Solidago chilensis had 
potent anti-inflammatory properties in pleural cavity inflammation in mice.157 This 
effect was much more potent than that of other above ground parts of the plant.  With 
more exploration into its therapeutic potential, plant root exudation may be a novel, 
renewable source of bioactive compounds that may be used in the treatment of 
metabolic diseases like NAFLD. 
TAURINE 
Taurine is an endogenous amino sulfonic acid involved in intracellular 
osmoregulation, bile acid formation, the central nervous system, retinal function, 
cardiac function, inhibition of protein phosphorylation and development. It is found in 
high intracellular concentrations in animal tissues and some algae. Taurine is crucial in 
transforming cholesterol to water soluble bile salts for cholesterol excretion, and is 




made, it is also taken up through taurine-rich sources such as seafood or shellfish, and 
this dietary uptake dictates plasma levels of taurine since vegans have taurine plasma 
levels that are only 50% that of omnivore levels.158  In high fat diet induced and 
genetically obese mice, as well as high fructose diet induced insulin resistant rats, 
plasma taurine concentrations were notably decreased compared to their respective 
controls.159,160 Dietary taurine supplementation prevented high fat diet induced obesity.  
While mice fed a high fat diet have decreased resting energy expenditure compared to 
high carbohydrate diet controls, this decrease was prevented with taurine 
supplementation.159,160  In high fructose diet fed rats, the characteristic hyperglycaemia, 
hyperinsulinaemia, and insulin resistance were all reduced with taurine 
supplementation. Taurine deficiency in humans has also been documented; obese 
patients had significantly lower plasma taurine levels than healthy controls (48±4 versus 
85±6 umol/liter, respectively) and patients with diabetes had significantly lower plasma 
taurine levels than in nondiabetic controls (32.1±1.9 versus 48.6±4.9 umol/liter, 
respectively).160-162 In a study done by Xiao et al., six overweight or obese nondiabetic 
male volunteers underwent 48 hour intravenous infusion of saline, intralipid and 
heparin to simulate chronic elevation of plasma NEFA, and intralipid and heparin with 
concurrent oral taurine supplementation.163  These conditions were randomized and 
spaced 4-6 weeks apart.163 Oral taurine supplementation ameliorated lipid induced 





Gestational taurine deficiency has been linked to impairments in the 
development of the pancreas. Female rats fed a normal diet plus taurine produce 
offspring that have weak glucose intolerance and islet cells are more sensitive to 
cytokines.164  Fetal islets from offspring of dams that were provided either a normal diet, 
a low protein diet, or a low protein diet supplemented with taurine during gestation, 
insulin secretion was normalized in the taurine supplemented group when compared to 
the low protein diet group, providing evidence that taurine is an essential nutrient in 
islet development.165  These results are supportive of the “thrifty phenoptype” 
hypothesis that links intrauterine growth retardation and the development of type 2 
diabetes later in life.166  Intrauterine growth retardation has also been linked to adult 
development of coronary heart disease, stroke, hypertension, and obesity.167 Thus, 
maternal taurine deficiency may contribute to the development of obesity and diabetes 
later in life.   
 
Taurine supplementation may also be directly beneficial in the treatment of 
NASH.  In a study by Chen et al., rats were either fed a standard control diet, a high fat 
diet, or a high fat diet with concomitant subcutaneous injection of taurine (for 8 weeks) 
for 12 weeks.168  Taurine treatment resulted in improved lipid and glucose metabolism, 
decreased TNF-α and TNF-β1 synthesis, increased synthesis of adiponectin, and had a 





NAFLD is on the rise, mirroring the increase in obesity in the United States. 
Treatments for this disease are non-specific and fraught with the same drawbacks as 
treatments aimed at obesity. We hypothesize that onion plant root exudates and 
taurine may provide a therapeutic tool for the treatment and/or prevention of NAFLD.     
SPECIFIC AIMS 
1. To determine whether onion plant root exudates can reduce hepatic fat 
accumulation and improve insulin signaling in vitro and/or in vivo. 
2. To determine whether taurine can reduce markers of oxidative stress, ER 
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 NAFLD is a metabolic disease that varies from simple steatosis to 
steatohepatitis (NASH), and can further progress to advanced fibrosis and cirrhosis.  
NAFLD is highly prevalent in cases of diabetes, obesity, cardiovascular disease and the 
metabolic syndrome, although it can exist in their absence.1-3  Recent estimates suggest 
that up to 30% of the general population have some form of NAFLD, up to 75% of 
patients with obesity and diabetes mellitus, and 80% of patients with metabolic 
syndrome have NAFLD.  Alarmingly, the recent increase in childhood obesity has 
resulted in a surge of type 2 diabetes and NAFLD in this population.4-7  There is no 
known recommended treatment specific to NAFLD; therapies such as gradual weight 
reduction, insulin sensitizers, antioxidants, and lipid-lowering agents are prescribed to 
treat diabetes, obesity, cardiovascular disease and/or metabolic syndrome and can 
improve NAFLD to various degrees.  However, these therapies have a number of side 
effects and are not designed to treat the specific characteristics of NAFLD, such as 




such treatments is not easily achieved in “susceptible populations” such as Native 
Americans, Hispanic and Latino Americans, and African Americans.8-15 A targeted 
therapeutic approach specific to the metabolic abnormalities of NAFLD and feasible for 
incorporation into the culture and lifestyle of these populations is crucial in preventing 
and treating development of NAFLD.  
 
A potential source of therapeutic compounds for NAFLD may exist in plants. 
Worldwide, over 1200 species of plants have been identified as traditional medicine for 
diabetes, but few have been experimentally evaluated.16  Several plant-based spices, 
such as fenugreek, garlic, onion, turmeric, and cumin have been shown to lower glucose 
levels in animals, and in the case of fenugreek and onion, in humans.17-19   
Unfortunately, the quantities required to achieve a glucose lowering effect appear to be 
excessive. 
 
In addition to bioactive compounds present within plants, plant roots secrete 
(exude) an enormous range of large and small molecular weight compounds into the 
rhizosphere, the soil zone that surrounds and is influenced by the roots of plants.20-22  
Compound synthesis and secretion by specialized root epidermal cells can be elicited by 
biotic and abiotic factors, and these compounds may or may not be present in the 
whole plant.20-23  Plant root exudates may constitute a novel frontier in the search for 





To determine whether onion plant root exudates can reduce hepatic fat 
accumulation and improve insulin signaling in vitro and/or in vivo. 
METHODS 
PROTOCOL FOR GROWING ONION PLANTS AND EXUDATE COLLECTION 
Onion seeds were surface sterilized with regular laundry bleach for one minute 
and subsequently washed with sterile double distilled water by vortexing four times 
before plating the seeds in Murashige and Skoog (MS, supplemented with 3% sucrose) 
agar plates. Surface sterilized seeds were plated on MS (with 3% sucrose) agar plates 
with the help of sterile forceps and plates were sealed with parafilm. After plating the 
seeds, plates were incubated in a growth chamber (Percivel Scientific Co.) at 25±2 oC 
with photoperiodism of 16 hours light and 8 hours dark for germination. Twelve-day-old 
seedlings from the MS agar plates were transferred in to MS liquid media (containing 3% 
sucrose) (25 seedlings per 250 ml MS liquid media) and incubated in an orbital shaker at 
25±3 oC with a photoperiodism of 16 hours light and 8 hours dark under cool white 
fluorescent light. Thirty days after transferring in to Liquid MS media, exudates were 
collected, filtered with Whatman filter paper and subsequently filter sterilized with 
0.45µm membrane filters to remove all the root sheathing cells and debris. The pH of 
the exudates was determined by using a Metler Toledo pH meter. Filter sterilized 
exudates were freeze-dried (Labconco). Onion seeds (Evergreen Long White Bunching, 




Skoog) salts were obtained from Caisson Laboratories, Inc., Product No. MSP0509. 
Membrane filters (0.45µm) were obtained from Millipore, Product No. HVLP04700.    
 
Freeze-dried onion root exudates were reconstituted in Dulbecco’s Modified 
Eagle’s Medium (DMEM) for cell experiments and saline for intraperitoneal injection 
into rats. The dosage used in cell-based experiments was the freeze-dried equivalent of 
1 ml of original exudate. In rats, this same quantity was provided in each injection. 
CELL CULTURE 
The rat hepatoma liver cell line, H4IIE, (American Type Culture Collection, 
Manassas, VI) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 
8 mM glucose and supplemented with 10% fetal bovine serum, penicillin and 
streptomycin sulfate. Experiments were performed at 80-100% cell confluence. To test 
the effects of onion root exudates on hepatic insulin signaling, H4IIE liver cells were 
treated overnight in the presence or absence of insulin (10 nM) in 6 ml of growth media 
(S) or 6 ml of growth media containing 1 ml reconstituted onion root exudate (E) per 
100mm plate. To test the effects of onion root exudates on hepatic lipid accumulation, 
H4IIE liver cells were treated for 24 hours in the presence or absence of oleate (500 uM) 
in 6 ml of growth media (S) or 6 ml of growth media containing 1ml reconstituted onion 
root exudate (E) per 100 mm plate.  Oleate (Sigma Chemical Co., St. Louis, MO) was 






LIPID MEASUREMENT IN H4IIE CELLS 
Triglyceride concentration. Total lipids were extracted using the methods of Bligh 
and Dyer.24  Total triglyceride content was determined enzymatically (Sigma Company, 
St. Louis, MO). 
Lipid extraction and methylation.  All glass tubes and pipettes were soaked in 
dilute HCl for 24 hours and ddH2O for 24 hours before each experiment.  
Methanol:chloroform (2:1) was added to samples immediately after harvesting.  The 
mixture was gassed with nitrogen and let stand for 2 hours while vortexing every thirty 
minutes.  The suspension was then filtered using Whatman paper #54 into a clean glass 
tube.  The original tube was washed with 1.5 ml methanol:chloroform:water (2:1:0.8).  
One ml chloroform and 1 ml ddH2O was added to the new tube, gassed with nitrogen, 
and shaken vigorously to mix.  The samples were centrifuged at 2500 rpm for 30 
minutes.  The lower layer was carefully transferred into a new tube.  The samples were 
evaporated to dryness under nitrogen and suspended with a small amount of 
chloroform:methanol (2:1).  The samples were stored at -20 °C under nitrogen.  Samples 
were methylated by adding 0.5 ml of 0.5 N methanolic NaOH and vortexed.  Samples 
were heated at 70 °C for 10 minute and cooled to room temperature.  Three ml of 
12.5% BF3:MeOH was added to each tube and heated for 30 minutes at 70 °C.  Samples 
were cooled to room temperature and 0.5 ml hexane and 1 ml ddH2O were added.  
Samples were then vortexed and allowed to separate.  The upper layer was removed 




Analysis of Fatty Acid Composition.  Samples were analyzed using an Agilent 
6890 Gas Chromatograph using helium as the gas carrier and a flame ionization 
detector. 
ANIMALS 
Male Wistar Crl(WI)BR rats (Charles River, Wilmington, MA) weighing 
approximately 180 g (7-8 weeks of age upon arrival) were used for the study.  They were 
housed individually in a temperature and humidity-controlled environment under 12 
hour light and dark cycles.  Food and water were provided ad libitum.  Bodyweight and 
food and water intake were monitored weekly.   Male Wistar rats were provided a high 
fat diet (HFD, Research Diets, New Brunswick, NJ, 45% of energy from corn oil, 35% from 
cornstarch, 20% from casein) or control diet (STD, Research Diets, New Brunswick, NJ, 
12% of energy from corn oil, 68% from corn starch, 20% from casein) for 4 wks 
accompanied by a daily IP injection of exudate (STDE or HFDE, n=9 per group, 
approximately 10.7 mg dried exudate in 200 ul sterile saline) or saline (STDS or HFDS, 
n=8).  After 4 wks, overnight fasted rats were anesthetized (sodium pendtobarbital, 50 
mg/kg), and blood and tissue samples obtained and processed for analysis. Protocols for 
animal experimentation and maintenance were carried out according to institutional 








REAL TIME RT-PCR 
Total RNA (2 ug) was isolated using TRIzol reagent (Life Technologies, Carlsbad, 
CA) according to the manufacturer’s instructions. Purified RNA was treated with DNAse 
(RQ1, Promega, Madison, WI) and reverse transcription (RT) was performed using 
Superscript II reverse transcriptase (Life Technologies, Carlsbad, CA). Transcribed cDNA 
was then subjected to polymerase chain reaction (PCR) amplification with IQ-SYBR green 
master mix (Bio-Rad, Hercules, CA, USA) using primers (Integrated DNA Technologies, 
Coralville, IA unless otherwise noted) specific for the genes listed below. All PCR 
reactions were run in duplicate with two individual preparations of reverse-transcribed 
cDNA. DNAse-treated RNA that had not been subjected to RT acted as a negative 
control.25,26 
 
Insulin Receptor Substrate-1 (IRS1, GenBank NM_012969),  
5'-GCCTGTCCTCTCCTACTACTC and 3'-CAGTTGCGGTATAGCGAAGG; 
 
Insulin Receptor Substrate-2 (IRS2, GenBank NM_001081212),  
5’-CTCTCCAGAGGCTTCATCCC-3’ and 3’-CCTCTGGATATGGCGGACG; 
 
V-Akt Murine Thymoma Viral Oncogene Homolog 1 (Akt1, NM_033230,  






Glucose-6-Phosphatase Catalytic Subunit (G6Pase; GenBank NM_013098),  
5'-GTGGGTCCTGGACACTGACT and 3'-AATGCCTGACAAGACTCCA;  
 
Phosphoenolpyruvate Carboxykinase (PEPCK; GenBank NM_198780),  
5'-GCTGGCAGCATGGGGTGTTTGTAGG and 3’-GACCTCACCTACAAGC; 
 
ß2-Microglobulin (used as a control; GenBank NM_012512),  
5'-GGTGACCGTGATCTTTCTGGTG and 3'-GGATGGCGAGAGTACACTTGAATT. 
PLASMA MEASURES 
Glucose was measured with an automated analyzer (Beckman Instruments, 
Fullerton, CA). Insulin was analyzed by ELISA (Linco Research, St. Charles, MO). Free 
fatty acid levels were determined using the WAKO NEFA-C kit (Richmond, VA).  
WESTERN BLOTTING 
Liver tissue or cells were homogenized using a lysis buffer containing 20 mM 
HEPES (pH 7.4), 1% Triton X-100, 10% glycerol, 2 mM EGTA, 1 mM sodium vanadate, 2 
mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 50 uM β-glycerophosphate, 3 
mM benzamidine, 10 uM leupeptin, 5 uM pepstatin, and 10 ug/ml aprotinin.  Total 
protein was measured according to the methods of Lowry et al.27 Equivalent amounts of 
protein (50-100 ug) was separated using SDS-PAGE, transferred to Hybond-P 
membranes (Amersham Pharmacia Biotech, Piscataway, NJ, USA), blocked and 




were used for protein detection: pAKT (serine 473, Cell Signaling), AKT (Cell Signaling), 
and actin (Sigma). Detection of proteins was done using horseradish peroxidase-
conjugated secondary antibodies (anti-rabbit, Santa Cruz Biotechnology), an enhanced 
chemiluminescence reagent (Santa Cruz Biotechnology), and a UVP bioimaging system 
(Upland, CA, USA) for optical density quantification.   
DATA ANALYSIS 
Statistical analysis was done using one way ANOVA where statistical significance 
was set at p<0.05.  All data are reported as means ± standard deviation. 
RESULTS 
TRIGLYCERIDE ACCUMULATION IN H4IIE LIVER CELLS. 
In the presence of 0.5 mM oleate incubation, H4IIE liver cells accumulated 
triglyceride.  This accumulation was prevented when cells were co-incubated with onion 
exudate (Figure 1A).  Similar results were observed with free fatty analysis by GC (data 
not shown).  
INSULIN SIGNALING IN H4IIE LIVER CELLS. 
Upon incubation with 10 nM insulin, H4IIE liver cells displayed increased insulin-
mediated phosphorylation of AKT, a protein involved in insulin signaling.  This insulin-
mediated phosphorylation of AKT was enhanced in the presence of onion exudates 
(Figure 1B).  In the absence of insulin, no increase in phosphorylation of AKT was 




IN VIVO EFFECTS OF ONION EXUDATES. 
Both HFDS and HFDE rats had significantly greater initial body weight than STDS 
rats (Table 1).  Food intake was not significantly different among groups.   Bodyweight 
gain was significantly greater in HFDS compared to STDS and HFDE (Table 1).   
Epididymal fat pad weight was significantly greater in HFDS than that of STDS rats, but 
not different from HFDE (Table 1). Retroperitoneal weights were not different between 
groups.  
 
Plasma glucose levels were significantly lower in HFDE compared to STDS and 
HFDS (Figure 2A).    Plasma insulin levels were significantly lower in HFDE compared to 
HFDS (Figure 2B). Plasma FFA levels were significantly reduced in HFDE rats with respect 
to HFDS (Figure 2C). Phosphorylation of AKT, a protein in the insulin signaling cascade, 
when normalized to AKT and insulin, was significantly increased in HFDE compared to 
HFDS (Figure 2D). Hepatic G6Pase (a gene that encodes the glucose-6-phosphatase 
protein, a protein that promotes release of glucose by the liver) mRNA was lower in 
HFDE compared to HFDS, and AKT mRNA was lower in HFDE compared to STDS 
(Figure 3).   
DISCUSSION 
The aim of this study was to examine the therapeutic potential of onion root 
exudates in NAFLD using both in vitro and in vivo models. Onion root exudates reduced 
fatty acid-mediated triglyceride accumulation and enhanced insulin-induced 




FFA, glucose, and insulin in rats fed a HFD. In addition, phosphorylation of AKT relative 
to insulin levels was normalized in the liver of rats fed a HFD and treated with onion root 
exudates. Overall, these results imply that onion root exudates contain bioactive 
compounds that may reduce hepatic steatosis from free fatty acids and improve insulin 
action.  
 
Onion contains a wide range of bioactive compounds that have been found to 
have potential therapeutic effects in vitro and in vivo.  Of significance to features of 
NAFLD, several studies have shown hypoglycemic, hypolipidemic, antioxidant, and anti-
inflammatory effects of onion in various models of diabetes, obesity and cardiovascular 
disease.28-44 Unfortunately, the amount of onion required to achieve these effects is 
quite high and therefore likely unrealistic from a dietary standpoint. Onion root 
exudation may provide a source of bioactive compounds that is renewable and effective 
at relatively low concentrations. 
 
In our study, oleate exposure in H4IIE liver cells caused intracellular 
accumulation of lipids, which was prevented with co-incubation of onion root exudates.  
Incubation of HepG2 liver cells with S-propyl cysteine, an extract of onion, reduced 
cellular triacylglycerol (TAG) and cholesterol ester synthesis from [14C]oleate, without 
affecting cellular TAG synthesis from [14C]acetate, suggesting that S-propyl cysteine 
reduced the transport of exogenous fatty acids into cells or fatty acid esterification.45 If 




cysteine, reduced transport of fatty acids into cells could be one possible mechanism by 
which triglyceride accumulation was prevented in liver cells; however, FFA 
disappearance from the media was not decreased in the presence of onion root 
exudate.  A reduction in cellular TAG could also result from increased release of TAG by 
hepatocytes; however we were unable to detect any TAG in the media. Therefore, we 
hypothesize that increased FFA oxidation may be the mechanism by which exudates 
prevent lipid accumulation in liver cells. 
 
Onion root exudates also enhanced insulin signaling in H4IIE liver cells.  Although 
the mechanisms leading to this enhancement are unknown, several possibilities can be 
considered. These include insulin mimetic effects, increased interaction of insulin with 
the insulin receptor or downstream signaling proteins to their respective targets, or by 
alterations in the activity of proteins involved in the propagation of the insulin signal 
(e.g. kinases) or  proteins involved in turning the insulin signal off (e.g. phosphatases).46-
51   It is unlikely that the increase in phosphorylation of AKT in the presence of exudates 
was  due to an insulin mimetic effect by the exudates, since there was no exudate-
derived signal enhancement in the absence of insulin (i.e. in the absence of insulin 
exudates did not increase pAKT). It is possible compounds present in onion root 
exudates could somehow enhance the ability of insulin to reach the insulin receptor 
(mobility effects). While mobility effects could be present, the rapid nature of the insulin 
signal under normal conditions and the increased expression of pAKT caused by the 




and/or attenuation of those proteins associated with the "off" signal. Pyridazine 
analogues have been shown to be noncompetitive reversible inhibitors of PTP1b 
(protein tyrosine phosphatase 1 beta, which dephosphorylates many proteins including 
pAKT), resulting in increased insulin-stimulated insulin receptor phosphorylation in 
vitro.50 Additionally, the synthetic vanadium compound TSAG0101 selectively inhibits 
PTP1b and resulted in blood glucose lowering effects in rats.46 Thus, since compounds 
exist that act on proteins involved in insulin signaling, a natural compound with similar 
properties is plausible.  
 
In rats fed a high fat diet, onion root exudates decreased fasting insulin levels 
and therefore improved whole body insulin action. In addition, onion root exudates 
increased pAKT relative to insulin in the liver. Improved pAKT is consistent with our in 
vitro data and suggests a similar mechanism of action.  The observed decrease in plasma 
insulin levels implies that exudates may have insulin sensitizing properties in tissues 
other than the liver.  Related to this, onion root exudates decrease plasma FFA levels.  
This implies that bioactive compounds present in these exudates influence adipose 
tissue lipolysis or FFA removal from plasma, and/or subsequent increased oxidation or 
storage.  Epididymal and retroperitoneal fat pad weights were not significantly different 
in HFD rats provided saline or exudate. If reduced adipose tissue lipolysis was the 
mechanism by which exudates caused the observed reduction of FFA, one might expect 
an increase in adipose tissue mass. It is also possible that the reduction of lipolysis was 




that were not measure were increased. It is also unlikely that decreased FFA were the 
result of increased plasma removal of FFA and subsequent storage in non-adipose 
tissue. This notion is generally incompatible with improved whole body insulin 
sensitivity. Food intake was not different among groups; however, HFDS rats had 
significantly greater body weight gain than STDS and HFDE. This may be due to the fact 
that the HFD had a higher caloric density than the STD. Energy expenditure resulting in 
increased oxidation is another possible mechanism by which exudates reduced fasted 
FFA and overall bodyweight. Regardless, improved insulin action was observed in both 
H4IIE liver cells and rat liver treated with onion root exudates and mechanistically may 
involve enhanced signal longevity, increased activity-induced fat oxidation, or 
suppression of adipose tissue lipolysis. 
 
Fasting plasma glucose levels were decreased in rats provided HFD and onion 
root exudates.  Improved insulin action in the liver could account for this via enhanced 
insulin suppression of glucose production. We examined genes associated with the 
insulin signaling and gluconeogenic pathways in the liver. Hepatic gene expression of 
insulin signaling (IRS1, IRS2, AKT) and gluconeogenic (G6Pase, PEPCK) enzymes failed to 
show a statistically significant perturbation induced by the exudates. These data imply 
that onion root exudates are most likely not acting at the level of transcription, however 
since these measurements represent only a "snapshot", exudates may act 
transcriptionally at a different time point than was measured. Exudate treatment 




lack of available antibodies) and may be a mechanism by which exudates lower fasting 
plasma glucose levels. The liver is the primary site for glucose production and G6Pase is 
the final enzymatic step converting glucose-6-phosphate to glucose.  It is well 
established that insulin potently inhibits G6Pase transcription.52 Thus, exudate-
mediated improvements in insulin signaling in the liver may explain the decrease in 
G6Pase mRNA. Further, if these changes also occur at the protein level, a reduction in 
glucose release by the liver could result. 
 
Augusti et al. demonstrated that s-methyl cysteine sulfoxide treatment of 
alloxan diabetic rats reduced hyperglycemia.  This effect was postulated to be due to a 
subtle insulin secretagogue effect on pancreatic β-cells, release of insulin from bound 
forms, or enhanced transport of blood glucose to peripheral tissue.54-57  Since our results 
indicate that onion root exudates reduce both insulin and glucose in rats provided a 
HFD, a compound distinct from s-methyl cysteine sulfoxide is likely involved.   
 
Future studies involving onion root exudates may elucidate the specific 
compounds and mechanisms by which they exert their bioactive effects.  Additionally, 
manipulations to the growth conditions of the onion plants may allow for increased 
preferential exudation of these bioactive compounds so that the overall potency of the 
resulting exudates is enhanced. We have successfully demonstrated that onion root 
exudates elicit physiologic responses when injected; however, the efficacy of orally 




studies can be attempted, there are a few major problems that must be addressed.  
First, since the initial in vitro and in vivo studies were from a pilot batch of exudates, 
documentation of the growth conditions and any manipulations of the exudates post 
harvest was lacking.  Experiments on subsequent batches of exudates have provided 
variable results.  At present, the reasons for this variability are unclear.  It is possible 
that the bioactive compounds in onion root exudates can vary diurnally.58 Until this is 
resolved, experiments to understand the significance and mechanisms of these initial 
observations cannot proceed.  
 
Onion root exudates display therapeutic effects on indices of NAFLD, namely 
reduced oleate-mediated lipid accumulation in H4IIE liver cells, improved insulin 
sensitivity and reductions in fasting glucose and FFA levels. While some of these effects 
have been observed with onion extracts, others, such as the reduction of plasma insulin, 
may be unique to onion root exudates.  If true, onion root exudates could provide a 
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Figure 1. Onion root exudates prevent lipid accumulation and enhance insulin signaling  
in liver cells. H4IIE liver cells were grown in 6 ml of growth media (S) or exudate-
reconstituted growth media (E) per plate. Cells were treated overnight in the presence 
or absence of  (A) oleate (500uM) or (B) insulin (10nM).  Data are presented as the mean 
± SDEV for n=3 (A) or n=8 (B). *, significantly (p<0.05) different from low-glucose 
controls; +, significantly (p<0.05) different from oleate or insulin controls. 
 
Figure 2. Onion root exudates decrease glucose, insulin, and FFA levels and increase 
pAKT.  Plasma  (A) glucose, (B) insulin,  (C) free fatty acid (FFA), and (D) insulin signaling 
(phosphorylation of AKT relative to plasma insulin levels) in overnight fasted rats 
following 4 wks of ad libitum exposure to a starch control diet (STD) or high fat diet 
(HFD) and daily injections of either saline (S) or onion exudates (E). Data are presented 
as the mean ± SDEV for n=8-9. *, significantly (p<0.05) different from STDS. #, 
significantly (p<0.05) different from HFDS. $, significantly (p<0.05) different from HFDE. 
 
Figure 3.  Hepatic expression of select insulin signaling and gluconeogenic genes.  Real 
Time PCR analysis of hepatic IRS1, IRS2, AKT, G6Pase, and PEPCK.  Data are presented as 
the mean ± SDEV for n=8. *, significantly (p<0.05) different from STDS. #, significantly 





Table 1: General and Metabolic Characteristics 
VARIABLE STDS HFDS HFDE 
 
Daily Food Intake, g 
 














Initial Body Weight, g 137.0 4.1 163.1 12.9* 159.8 6.0* 
    


















Table 1.  General and metabolic characteristics of rats fed either Starch Control Diet 
with daily saline intraperitoneal injection (STDS, n=6), High Fat Diet with daily saline 
intraperitoneal injection (HFDS, n=8), or High Fat Diet with daily exudate intraperitoneal 
injection (HFDE, n=8).  +, the amount of exudate is estimated to be 10.7 mg/rat/day. *, 
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THE PROTECTIVE EFFECTS OF TAURINE ON NUTRIENT-INDUCED HEPATIC 
ENDOPLASMIC STRESS, OXIDATIVE STRESS AND CELL DAMAGE 
 
BACKGROUND 
Non-alcoholic fatty liver disease (NAFLD) is a burgeoning metabolic disorder 
characterized by fatty infiltration of the liver (steatosis) with progression, in some, to 
non-alcoholic steatohepatitis (NASH) and liver failure.1,2  Presently, NAFLD is estimated 
to affect upwards of 24% of the general population, as well as 3–9% of all children in the 
United States.3,4  Of great concern are statistics indicating that, within 10 years of 
diagnosis, nearly 20% of the patients presenting with NASH progress to cirrhosis.5-7  
Recent data also suggest that NAFLD is independently associated with the development 
of cardiovascular disease and overall-obesity-related mortality.8-11 Thus, in light of these 
data, there is a critical need to elucidate the mechanisms that mediate the development 
and progression of NAFLD, and to identify potential therapies for the disease. 
 
Although the pathogenesis of NAFLD remains uncertain, it has been suggested 
that various factors, including oxidative stress, pro-inflammatory cytokines, gut-derived 




progression of the disease.12  Accumulation of lipids in non-adipose tissues can lead to 
cell dysfunction such as insulin resistance and cell death, a phenomenon known as 
lipotoxicity.13  Experimental and clinical data indicate that excess fatty acids, in 
particular long chain saturated fatty acids, are an important determinant of liver cell 
integrity, liver function, and potentially, an independent risk factor for the progression 
from NAFLD to NASH.14-16 
 
An accumulating body of literature suggests that an important factor linking 
excess fatty acids to liver damage is dysfunction of the endoplasmic reticulum (ER). One 
of the largest subcellular organelles, the ER plays an important role in the correct 
assembly of proteins destined for intracellular organelles and the cell surface.17  We and 
others have demonstrated that saturated fatty acids induce markers of ER stress, an 
indicator of disrupted ER homeostasis, in liver cells.18,19  We have also demonstrated 
that diets which produce hepatic steatosis characterized by increased saturated fatty 
acids (e.g. high saturated fat or high sucrose diets) lead to ER stress and liver injury.14 
 
Furthermore, multiple markers of ER stress have been observed in livers taken 
from genetic models of obesity20 and in livers and adipose tissue from obese patients 
with NAFLD.21,22  There is no proven, effective therapy for NAFLD; thus, lifestyle 
modifications, similar to those recommended for obesity, remain the primary treatment 




is a pressing need for therapeutic strategies that might prevent NAFLD in the continuing 
presence of high-fat and/or high sugar diets. 
Taurine, 2-aminoethanesulfonic acid, is a major intracellular amino sulfonic acid 
with diverse physiological functions. Taurine supplementation may be beneficial in 
preventing various metabolic disorders, including obesity, insulin resistance, and 
atherosclerosis.24,26  Increasing evidence also suggests that taurine may have beneficial 
effects on NAFLD.27  Also, taurine supplementation prevents alcoholic fatty liver disease 
in experimental animals,28 and mice characterized by hetero- or  homozygous knockout 
of the taurine transporter develop chronic liver disease characterized by fibrosis, 
inflammation and hepatocyte apoptosis.29  Plasma taurine levels are also decreased in 
various forms of liver cirrhosis.30,31 Interestingly, the beneficial effects of taurine are 
often accompanied by reductions in ER stress, suggesting a link between the therapeutic 
properties of taurine and restoration of ER homeostasis.32-34 
 
The present study was undertaken to examine the effects of taurine 
supplementation on cell and animal models of NAFLD with a view to assessing its 
potential as a preventative treatment. Our findings demonstrate that taurine mitigates 
palmitate-induced ER stress and apoptosis in primary hepatocytes and H4IIE liver cells. 
Taurine reduced ER and oxidative stress in sucrose-fed rats and ER stress and lipid 
accumulation in tunicamycin-treated mice. Collectively, our results indicate that part of 




of ER stress and that dietary supplementation with this compound offers significant 
potential as a preventative treatment for this disease. 
METHODS 
EXPERIMENTAL AGENTS 
Fatty acids (Sigma Chemical Co., St. Louis, MO) were complexed to bovine serum 
albumin at a 2:1 molar ratio.35  Taurine and tunicamycin were purchased from Sigma.  
CELL CULTURE 
The rat hepatoma liver cell line, H4IIE, (American Type Culture Collection, 
Manassas, VI) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 
8 mM glucose and supplemented with 10% fetal bovine serum, penicillin and 
streptomycin sulfate. Experiments were performed at 80-100% cell confluence. In 
preparation for primary cell culture, hepatocytes were isolated from male, Wistar rats 
(Charles River Laboratories, Wilmington, MA) by collagenase perfusion.36,37 All 
procedures involving rats were reviewed and approved by the Colorado State University 
Institutional Animal Care Committee. Cells were first incubated in Roswell Park 
Memorial Institute media (RPMI; HyClone, Logan, UT) containing 11 mM glucose, 10-7 M 
dexamethasone, and 10-7 M insulin on Matrigel- coated plates (for RNA) or on collagen-
coated plates containing 5% fetal bovine serum (for protein) for 4h (attachment period). 
The medium was then changed to one containing RPMI, 8 mM glucose, 10-7 M 
dexamethasone, and 10-8 M insulin. The following morning experimental treatments 




(control low glucose medium, LG). Each independent experiment was performed in 
triplicate. 
ANIMALS 
Male Wistar Crl(WI)BR rats (Charles River, Wilmington, MA) weighing 180 g (7–8 
wk of age) on arrival were provided free access to a purified high-starch diet (68% of 
energy from cornstarch, 12% from corn oil, and 20% from casein; Research Diets, New 
Brunswick, NJ)38 and water for 1 wk. Rats were housed individually in a temperature- 
and humidity-controlled environment with a 12-h light, 12-h dark cycle. All procedures 
were reviewed and approved by the Colorado State University institutional animal care 
committee. After the 1 wk acclimation period, rats were fed either the high starch diet 
(STD) or a high sucrose diet (HSD; 68% of energy from sucrose, 12% from corn oil, 20% 
from casein; Research Diets, New Brunswick, NJ)38 for 4 weeks. Dietary groups were 
randomly assigned to either normal drinking water (n=6 per diet) or to drinking water 
that contained taurine (2% w/v; n=6 per diet). Water and food intake were measured 
every other day and body weight was measured weekly. 
 
Male, C57BL/6J mice (7-11 wks) were housed in colony cages and maintained on 
a 12-hour light/dark cycle. Mice were randomly assigned to one of four treatment 
groups (n=6 for each group): 1) control, IP injected with PBS;  2) taurine, mice were 
provided taurine (2.0% w/v added to the drinking water) for one week prior to sham 
injection with PBS; 3) tunicamycin, IP injected with tunicamycin ) and 4) tunicamycin + 




week prior to IP injection with tunicamycin. Previous work has shown that the dose of 
tunicamycin used (0.5 mg/kg body weight) results in lassitude, lack of grooming, weight 
loss, liver injury and hepatic steatosis that peaks between day 4 and 5 post-injection.39 
In groups 2 and 4, taurine treatment was maintained until sacrifice at four days post 
vehicle/tunicamycin injection. Four days post injection, all mice were anaesthetized 
(isoflourane/oxygen) and sacrificed by decapitation, and blood samples were collected 
for plasma analysis. Livers were removed, weighed and then samples were 
either immersion-fixed overnight in 4% paraformaldehyde in PBS (pH 7.3) for 
subsequent histological analysis or were snap frozen in liquid nitrogen and examined for 
morphological, histological and biochemical analyses. The animal care and procedures 
were approved by the Animal Care and Use Committee of the University of Colorado at 
Denver Health Sciences Center and the Guide for the Care and use of Laboratory 
Animals prepared by the National Academy of Sciences.  
RNA ISOLATION AND ANALYSIS 
Total RNA was extracted with TRIzol reagent using the manufacturer’s protocol 
(Invitrogen, Carlsbad, CA). For analysis of XBP1 splicing, a two-step protocol was used 
for reverse transcription polymerase chain reaction (PCR) using Superscript II reverse 
transcriptase and Taq polymerase.36  For Real Time PCR, reverse transcription was 
performed using 0.5 μg of DNase-treated RNA, Superscript II RnaseH- and random 
hexamers. PCR reactions were performed in 96 well plates using transcribed cDNA and 
IQ-SYBR green master mix (Bio Rad, Hecula, CA). Primer sets can be found in a previous 




linear over 5 orders of magnitude. The specificity of products generated for each set of 
primers was examined for each fragment using a melting curve and gel electrophoresis. 
Reactions were run in triplicate and data calculated as the change in cycle threshold 
(ΔCT) for the target gene relative to the ΔCT for β2-microglobulin and cyclophilin 
(control genes) according to the procedures of Muller et al.40 Results were similar 
regardless of the control gene; therefore data in the results section are reported using 
β2-microglobulin and normalized to 18S mRNA.  
IMMUNOBLOT ANALYSIS 
Cells and liver tissue were processed as described previously.14  Equivalent 
amounts of protein (50μg) were subjected to SDS-PAGE, transferred to Hybond-P 
membranes (Amersham Pharmacia Biotech, Piscataway, NJ), and the membranes 
incubated with antibodies against glucose regulated protein 78 (GRP78; Stressgen, Ann 
Arbor, MI), phospho-eukaryotic initiation factor 2-α (p-eIF2α; Cell Signaling, Waverly, 
MA), eIF2α (Cell Signaling), C/EBP homologous protein (CHOP; Santa Cruz 
Biotechnology, Santa Cruz, CA) and/or beta-actin (Sigma). Proteins were detected using 
horseradish peroxidase-conjugated secondary antibodies and an enhanced 
chemiluminescence reagent (Pierce, Rockford, IL). Density was quantified using a UVP 
Bioimaging system (Upland, CA). 
DETERMINATION OF CASPASE ACTIVITY AND CELL DEATH 
Activity of the caspase-3 class of cysteine proteases was determined with the 




conjugated to the color reporter molecule p-nitroanaline (R & D Systems, Minneapolis, 
MN). Caspase activity was normalized to cell lysate protein concentration. Cell death 
was examined using the Cell Death Detection ELISA kit (Roche Diagnostics, Penzberg, 
Germany). The assay is based on the quantitative sandwich-enzyme immunoassay-
principle using mouse monoclonal antibodies directed against DNA and histones. This 
allows specific determination of mono- and oligo-nucleosomes in the cytoplasmic 
fraction of cell lysates.  
DCF FLUORESCENCE AND PROTEIN CARBONYL FORMATION 
Oxidative stress was estimated using 2,7- dichlorofluorescein di-acetate (DCFH-
DA).41  This assay is based on the ability of DCFH-DA to diffuse across the cell membrane 
and, following enzymatic hydrolysis to DCFH, oxidized to the fluorescent compound DCF 
(2’,7’-dichlorodihydrofluorescein). Following treatments, cells were loaded with 5 μM 
DCFH-DA (Molecular Probes), using serum free media, for 45 min at 37ºC.42 
Fluorescence was monitored with excitation and emission wavelengths of 490 and 535 
nm, respectively. Data are reported as the fold increase in median fluorescence over 
control cells. Protein carbonyls were measured in H4IIE liver cells using an ELISA-based 
kit (Biocell, New Zealand). Briefly, protein samples were reacted with 
dinitrophenylhydrazine (DNP) at room temperature for 45 min, after which time 
samples were rinsed and a blocking solution was added for 1 h. Anti-DNP antibody and, 
subsequently, a secondary antibody, were both added for 1 h. Finally, substrate buffer 





Paraffin embedded sections were stained with hematoxylin and eosin to 
evaluate steatosis and inflammatory infiltrate. 
IMMUNOHISTOCHEMISTRY 
Paraffin embedded liver samples were cut as 4-μm-thick serial sections. The 
unfolded protein response (UPR) was analysed using an anti-KDEL monoclonal antibody 
(SPA-827), which recognizes both glucose regulated protein (GRP)78/BiP and GRP94 
(StressGen Biotechnologies Corp. Ann Arbor, MI). The anti-CHOP polyclonal antibody 
(sc-575) was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, California, USA). 
Anti-KDEL was diluted 1/50 and used without antigen retrieval. Rabbit anti-CHOP 
polyclonal antibody was diluted 1/40 and applied after heat retrieval in Retrieve-all 2 
(Signet Laboratories) at 95°C for 30 minutes and a 10-minute incubation in 0.1% Triton 
X. Sections were deparaffinized, and the endogenous peroxidase activity was blocked 
with 0.5% H2O2 in methanol for 10 minutes. After blocking with 5% normal goat serum, 
sections were incubated with primary antibody for 1 hour at room temperature, 
followed by goat antirabbit, or rabbit anti-mouse biotinylated secondary antibodies 
(Vector Laboratories), diluted 1/500 in 0.05 mol/L Tris buffer, pH 7.5, for 30 minutes, 
and streptavidin-peroxidase (Zymed Laboratories), diluted 1/20, for 5 minutes. Sections 
were developed in Nova Red peroxidase substrate (Vector Laboratories) and 
counterstained with hematoxylin. Nonspecific immunostaining was not detected in 
sections stained with nonimmune IgG as the primary antibody or with the secondary 





Liver lipid was extracted using the procedure of Bligh and Dyer.43  Triglyceride 
concentration was determined using a kit (Sigma).  
PLASMA MEASURES 
Glucose was measured with an automated analyzer (Beckman Instruments, 
Fullerton, CA). Insulin and C-reactive protein (CRP) were analyzed by ELISA (Linco 
Research, St. Charles, MO and Helica, Fullerton, CA, respectively). Plasma tumor 
necrosis factor (TNF)-alpha levels were determined by ELISA (R and D systems). In order 
to assess the level of oxidative stress, plasma levels of reactive aldehydes formed by 
lipid peroxidation were determined using a thiobarbituric acid reactive substances 
(TBARS) assay. TBARS determinations were carried out with an OXI-TEK TBARS Assay Kit 
(Alexis Biochemicals, San Diego, California, USA) according to the manufacturer’s 
standard protocol with modifications as described previously.44  Results were expressed 
as nmol malondialdehyde (MDA) equivalents/mL for plasma samples. Plasma 
triglycerides were determined enzymatically (Sigma Company, St. Louis, MO) and free 
fatty acid levels were determined using the WAKO NEFA-C kit (Richmond, VA). Aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) were analyzed using kits 




 DATA ANALYSIS AND STATISTICS 
Statistical comparisons were calculated using analysis of variance and post-hoc 
comparisons among means using the Scheffe’s or Tukey’s test. Statistical significance 
was set at p<0.05. All data are reported as the means ± SDEV. 
RESULTS 
EFFECTS OF TAURINE ON PALMITATE-MEDIATED CELL DEATH IN LIVER CELLS 
We have previously reported that saturated fatty acids, but not unsaturated 
fatty acids, cause liver cell death.35,45  Palmitate- mediated cell death appears to be 
caspase-dependent and is consistently present after 16 h but not 6 h incubations.35,45  In 
the present study, we first examined the effects of taurine on palmitate mediated 
caspase-3 activity and liver cell death. The unsaturated fatty acid oleate was used as a 
negative control. Taurine significantly reduced palmitate-mediated induction of caspase-
3 activity and cell death in H4IIE liver cells and primary hepatocytes following 16 h 
incubations at palmitate concentrations of 500 μM, but not at 250 μM (Figure 1). 
Taurine did not significantly affect the cellular utilization of glucose or free fatty acids 
based on the net loss of these nutrients from the medium (data not shown). 
EFFECTS OF TAURINE ON PALMITATE-MEDIATED ER STRESS IN LIVER CELLS 
Disruption of ER homeostasis, collectively termed ER stress, activates the UPR.46 
The UPR is initiated by three ER transmembrane proteins, inositol requiring ER-to-
nucleus signaling protein 1α (IRE1α), RNA dependent protein kinase-like ER eukaryotic 




Activation of IRE1α promotes the splicing of X-box-binding protein-1 (Xbp1) mRNA and 
subsequent transcription of molecular chaperones (e.g. GRP78) and genes involved in 
ER-associated degradation.48 PERK activation leads to phosphorylation of the α-subunit 
of the translation initiation factor eIF2 and subsequent attenuation of translation 
initiation, as well as increased expression of GRP78, CHOP, a pro-apoptotic gene, and 
growth arrest and DNA damage-inducible protein 34 (GADD34).48,49  GADD34 mediates 
dephosphorylation of eIF2α and therefore reversal of translational attenuation.47 
Activation of ATF6 can also lead to increased expression of both molecular chaperones 
and CHOP. Taurine reduced, but did not prevent, the palmitate-mediated increase in 
gene and protein markers of ER stress and UPR activation in H4IIE liver cells (Figure 2) 
and primary hepatocytes (Figure 3). Taurine had little or no effect on palmitate-
mediated Xbp1 splicing in either cell type (Figures 2 and 3). 
EFFECTS OF TAURINE ON PALMITATE-MEDIATED OXIDATIVE STRESS 
Reduced oxidative stress has been identified as a potential mechanism by which 
taurine exerts its protective effects. The anti-oxidant properties of taurine include the 
ability to scavenge reactive oxygen species and reduce lipid peroxidation.50,51  Thus, we 
next examined the effects of taurine on palmitate-mediated oxidative stress. Palmitate, 
but not oleate, increased (p<0.05) DCF fluorescence in both H4IIE liver cells (Figure 4A) 
and primary hepatocytes (Figure 4B), and these effects were prevented by co-incubation 
with taurine. Time course studies revealed that the palmitate-mediated increase in DCF 
fluorescence was observed after 2 h and was maximal after 6 h (data not shown). Dose-




DCF fluorescence (data not shown). Additionally, palmitate, but not oleate, increased 
protein carbonyls, and the presence of taurine significantly reduced this effect in H4IIE 
liver cells (Figure 4C). 
EFFECTS OF TAURINE ON HIGH SUCROSE DIET-INDUCED HEPATIC STEATOSIS, ER STRESS, 
INFLAMMATION AND LIVER INJURY 
To date, the role of dietary fat and blood lipids in obesity and NAFLD/NASH have 
probably attracted the majority of attention. However, it is important to realize that 
carbohydrate, the macronutrient that typically tends to increase as a percentage of total 
caloric intake when fats are restricted, may not be a totally desirable nutrient either.14,52  
Previous work in our laboratory has shown that a high sucrose diet induces hepatic 
steatosis characterized by increased saturated fatty acids, ER stress, liver injury and 
insulin resistance in rats.14,53,54  It is possible that excess dietary fat and excess dietary 
sucrose exert similar pathogenic effects in the liver but through functionally distinct 
mechanisms. In order to further investigate the therapeutic potential of taurine in 
NAFLD/NASH, we examined the effects of taurine supplementation in a rat model of 
high sucrose diet-induced NAFLD. Taurine supplementation in the drinking water of rats 
provided the high sucrose diet significantly (p<0.05) reduced plasma insulin, and plasma 
triglycerides (Table 1). Hepatic triglycerides were reduced by 21% (Table 1; and the 
neutral lipid pool was clearly reduced based on oil-red O staining, Supplemental Figure 
1). Taurine also reduced gene and protein markers of ER stress (Figure 5, Supplemental 
Figure 2), oxidative stress (plasma TBARS (Fig. 6A)), and inflammation (TNFα (Figure 6B), 




liver injury as assessed by plasma ALT and AST levels (Figures 6E and F) in rats provided 
the high sucrose diet compared to the relevant controls. Collectively, this data indicates 
that taurine supplementation has significant therapeutic potential in preventing NAFLD 
and liver injury induced by excessive consumption of sucrose. 
EFFECTS OF TAURINE ON HIGH SUCROSE DIET-INDUCED HEPATIC GENE EXPRESSION 
In an effort to determine potential targets of taurine under conditions of high 
sucrose diet, we examined a number of genes whose protein products affect pathways 
implicated in NAFLD. The following  representative genes were screened: ER/UPR stress 
(GRP78, GADD34, Chop), inflammation (SAP, CRP), lipogenesis (FAS, ACCα, ACCβ, 
SREBP1c, SCD1, ChREBP), fatty acid oxidation (CPT1α, PGC1α, PPARα) and fatty acid 
transport (FABP1, FABP5). Of these, ACCα (Figure 7B), CRP (Figure 6C), GRP78 (Figure 
5A), GADD34 (Figure 5B), and Chop (Figure 5C) were significantly reduced in HSD fed 
rats treated with taurine.  Although FAS followed this trend (Figure 7A) it was not 
statistically significant.  
EFFECTS OF TAURINE ON TUNICAMYCIN INDUCED HEPATIC STEATOSIS, LIVER INJURY AND 
UPR INDUCTION 
The experiments described above indicate that taurine may  exert  protective 
effects in diet  induced NAFLD by ameliorating oxidative stress, inflammation and ER 
stress. A major complication  to our understanding of the protective mechanisms of 
taurine supplementation is  the fact that these  pathogenic features are interrelated 
phenomena, with each capable of inducing  the other.55,56  In an  effort to dissect the 




induced steatosis and liver injury as described in the materials and methods.  
Tunicamycin causes ER stress and induction of the UPR by inhibiting UDP-N-
acetylglucosamine:dolichol phosphate N-acetylglucosamine-1-P transferase, and 
thereby blocking  protein N-glycosylation. In this model, ER stress is the primary 
initiating factor and any resultant oxidative stress and/or inflammation will be 
downstream consequences of the treatment.    Tunicamycin injection resulted in hepatic 
steatosis and concomitant increases in liver weight, plasma ALT and liver lipid content 
(Figure 8). Hepatic lipid accumulation and liver injury were significantly attenuated by 
taurine supplementation (Figure 8). The effect of taurine upon tunicamycin mediated 
induction of the UPR was analyzed by immunohistochemistry. This analysis revealed 
that taurine supplementation reduced the induction of proteins containing the KDEL 
signal sequence and completely ablated tunicamycin induced expression of CHOP 
(Supplemental Figure 3). These results are consistent with the possibility that taurine 
exerts hepatoprotective effect in NAFLD at least in part by reducing ER stress. 
DISCUSSION 
This study provides insight into the therapeutic role of taurine in metabolic 
dysfunction associated with hepatic steatosis, which is often present in conditions of 
obesity, type 2 diabetes, and the metabolic syndrome.  Taurine is a small amino 
sulphonic acid which can be obtained through the diet or synthesized endogenously 
from methionine and cysteine.57 Taurine aids in numerous physiological processes, 
including bile salt formation, osmoregulation, central nervous system function, and 




(palmitate, high sucrose diet) and chemically-(tunicamycin) induced hepatic steatosis, 
ER stress, inflammation and injury. Importantly, the beneficial effects of taurine were 
consistent across four models: palmitate incubation of isolated primary hepatocytes and 
H4IIE liver cells, long-term (4-wk) high sucrose feeding in rats and acute tunicamycin 
injection in mice.  
 
Other studies have also shown protective effects of taurine in models of 
diabetes, atherosclerosis, obesity, and a variety of forms of liver injury including 
steatosis.  This study adds to the literature in suggesting possible mechanisms by which 
taurine exerts its beneficial effects in preventing dysfunction.  For example, substantial 
evidence indicates that taurine protects a wide variety of cells from oxidative damage by 
increasing antioxidant defense systems,33,59 decreasing the formation of ROS,60,61 and 
interfering with ROS activity.62,63  In the present study, taurine reduced 1) palmitate-
mediated protein carbonyl formation in H4IIE liver cells, which is elevated in patients 
suffering from NAFLD or type 2 diabetes;64-66  2) palmitate-mediated DCF fluorescence in 
H4IIE liver cells and primary hepatocytes; and 3) reduced plasma TBARS in high sucrose 
diet fed rats. Collectively these results suggest that taurine, directly or indirectly, can 
mitigate oxidative stress in the liver. 
 
The ER provides a unique oxidizing environment for protein folding and disulfide 
bond formation. Each disulfide bond formed during oxidative protein folding produces a 




million disulfide bonds per minute, thus it has been postulated that protein folding in 
the ER is intimately linked to oxidative stress.56,67,68 Indeed, oxidants not only provoke 
ER stress but also are signals generated by misfolded proteins in the ER that then 
activate the UPR and can lead to cell death.56,67,68  In the present study, taurine reduced 
or prevented palmitate-, sucrose-, and tunicamycin-mediated ER stress and UPR 
activation. These results are consistent with recent reports indicating that taurine 
mitigates ER stress in lung tissue and vascular cells following various insults,32-34 and 
suggest that attenuation of ER stress may be an important mechanism by which taurine 
leads to reduced inflammation, liver injury and cell death. 
 
High sucrose diets are characterized by their ability to induce hepatic steatosis 
primarily through lipogenesis.   Interestingly, this diet also results in the induction of the 
UPR, which has recently been linked to lipid biosynthesis control, fatty acid oxidation, 
and lipoprotein secretion.69-72 A recent study showed that taurine reduced the 
expression of genes involved in de novo lipogenesis (e.g. Scd2, Elovl6, ACCa, and FAS) in 
ob/ob mice.73  Our high sucrose diet study may further support this observation in that 
initial RNA screening showed a significant reduction in ACCa mRNA and a trend towards 
reduction in FAS mRNA.  In the livers of high carbohydrate diet fed mice, activation of 
the IRE1a/XBP-1 UPR branch directly controlled expression of genes involved in fatty 
acid biosynthesis, including ACC.74,75  It is therefore possible that the ability of taurine to 




Chronic ER stress and activation of the UPR has been linked to impairments in 
insulin action, activation of inflammatory cascades and the innate immune response, 
and apoptosis.76-78 Thus, it is attractive to suggest that the ability of taurine to reduce 
palmitate-mediated cell death, inflammation (based on TNFα and CRP) and liver injury 
results from a centralized effect on ER homeostasis. However, a few observations from 
the present study suggest that the effects of taurine may be more complex. First, in liver 
cells taurine reduced ER stress markers at both concentrations of palmitate but 
significant reductions in caspase-3 activity and cell death were only observed at the 
higher concentration of palmitate. Thus, chronic ER stress and UPR activation are clearly 
not the only mediators of palmitate-mediated cell death. Second, taurine did not reduce 
palmitate-mediated Xbp1 splicing. Although this may be due to the inability to detect 
small changes in Xbp1 splicing it suggests that the IRE1 branch of the UPR may remain 
active in the presence of taurine. The ability to maintain activation of this branch of the 
UPR has been linked to cell survival,79 thus the maintenance of Xbp1 splicing in cells may 
be linked to reduced cell death. 
 
Despite dietary and lifestyle recommendations, nutrient excess-related disorders 
such as obesity and NAFLD are on the rise.  Given the therapeutic potential of taurine to 
alleviate metabolic impairments associated with these diseases, supplementation could 
have advantages on the health of those afflicted, with the additional benefit of reduced 
healthcare costs. Taurine is already supplemented in infant total parenteral nutrition 




development.80,81 Adult supplementation, in particular to those at risk for metabolic 
diseases, does not seem so farfetched in that it is inexpensive, nontoxic, and can be 
orally administered.  
 
There are some limitations of the current study that should be noted. In regards 
to DCF fluorescence as a marker of oxidative damage, we cannot rule out the possibility 
that reactive species that do not react with DCFH may remain operative in the presence 
of taurine and therefore we have underestimated the contribution of oxidative stress to 
palmitate-mediated cell damage and death. Also, the use of this probe to estimate 
oxidative stress during apoptosis should be approached with caution, as cytochrome c is 
a powerful catalyst of DCFH oxidation.42 A high fat diet could have also been used to 
further examine taurine’s effects on lipotoxicity, however Wistar rats are resistant to 
high fat diet-induced steatohepatitis.82  Finally, although the results of the current 
experiments suggest that the beneficial effects of taurine are accompanied by 
reductions in oxidative stress and ER stress, the methods employed cannot determine 
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Figure 1. Fatty Acid-Mediated Cell Death in H4IIE Liver Cells and Primary Hepatocytes. 
(A) Caspase-3 activity; (B) ELISA-based cell death in H4IIE liver cells and primary 
hepatocytes. Cells were incubated for 16 h in control media (LG) or LG supplemented 
with albumin-bound oleate at 250 μM (O250), oleate at 500 μM (O500), palmitate at 
250 μM (P250) or palmitate at 500 μM (P500) in the absence (no additions) or presence 
of taurine (1% w/v). Values are means ± SD for n=6-8 independent experiments. * = 
significantly different from same condition without taurine. 
 
Figure 2. Fatty Acid-Mediated ER Stress in H4IIE Liver Cells. (A) CHOP and GADD34 mRNA 
relative to 18S; (B) Unspliced (u) and spliced (s) Xbp1 mRNA; and (C) GRP78, 
phosphorylated eIF2α (p-eIF2α), total eIF2α and actin protein. Incubations were exactly 
as described in figure 1 with the exception that the duration of the incubations was 6 h. 
In graphs, values are means ± SD for n=6-8 independent experiments and gels are 
representative of n=6-8. Note the different order of treatments between blot and graph 
for eIF2α. * = significantly different from same condition without taurine. 
 
Figure 3. Fatty Acid-Mediated ER Stress in Primary Hepatocytes. (A) CHOP and GADD34 
mRNA relative to 18S; (B) Unspliced (u) and spliced (s) Xbp1 mRNA; and (C) GRP78, 
phosphorylated eIF2α (p-eIF2α), total eIF2α and actin protein. Incubations were exactly 
as described in figure 1 with the exception that the duration of the incubations was 6 h. 
Values in graphs are means ± SD for n=6 independent experiments and gels are 
representative of n=6. Note the different order of treatments between blot and graph 
for GRP78 and eIF2α. * = significantly different from same condition without taurine. 
 
Figure 4. Fatty Acid-Mediated Oxidative Stress in H4IIE Liver Cells and Primary 
Hepatocytes. (A) DCF fluorescence in H4IIE liver cells; (B) DCF fluorescence in primary 
hepatocytes; (C) protein carbonyl formation in H4IIE liver cells. Incubations were exactly 
as described in figure 1 with the exception that the duration of the incubations was 6 h. 
Values are means ± SD for n=3-6 independent experiments. * = significantly different 
from same condition without taurine. 
 
Figure 5. The Effects of Taurine on Gene Markers of ER Stress in Rats Provided a High 
Starch or High Sucrose Diet. (A) GRP78 mRNA, (B) GADD34 mRNA; (C) Chop mRNA 
relative to 18S. STD, high starch diet for 4 wks; STD+T, high starch diet and drinking 
water with 2% (w/v) taurine for 4 wks; HSD, high sucrose diet for 4 weeks; HSD+T, high 
sucrose diet for 4 weeks and drinking water with 2% taurine (w/v). Values are means ± 





Figure 6. The Effects of Taurine on Markers of Oxidative Stress, Inflammation and Liver 
Enzymes in Rats Provided a High Starch or High Sucrose Diet. (A) Plasma thiobarbituric 
acid reactive substances, (TBARS); (B) Plasma tumor necrosis factor-α, (TNFα); (C) C-
reactive protein mRNA relative to 18S, (CRP); (D) Plasma CRP; (E) Plasma alanine 
aminotransferase, (ALT); (E) Plasma aspartate aminotransferase (AST). STD, high starch 
diet for 4 wks; STD+T, high starch diet and drinking water with 2% (w/v) taurine for 4 
wks; HSD, high sucrose diet for 4 weeks; HSD+T, high sucrose diet for 4 weeks and 
drinking water with 2% taurine (w/v). Values are means ± SD for n=4-6 per group. * = 
significantly different from all other groups. 
 
Figure 7. The Effects of Taurine on Lipogenic Gene Expression in Livers of Rats Provided 
High Starch or High Sucrose Diet. (A) FAS; (B) ACCα relative to 18S. STD, high starch diet 
for 4 wks; STD+T, high starch diet and drinking water with 2% (w/v) taurine for 4 wks; 
HSD, high sucrose diet for 4 weeks; HSD+T, high sucrose diet for 4 weeks and drinking 
water with 2% taurine (w/v). Values are means ± SD for n=4-6 per group. * = 
significantly different from all other groups. 
 
Figure 8. The Effects of Taurine in Mice Injected with Tunicamycin. (A) Liver weight; (B) 
H&E stain and liver triglycerides; (C) alanine aminotransferase (ALT). Con, carrier 
injected; Con + Tau, carrier injected and provided taurine in drinking water; Tun, 
tunicamycin injected; Tun + Tau, tunicamycin injected and provided taurine in drinking 








Table 1: General and Metabolic Characteristics 
VARIABLE STD STD+T HSD HSD+T 





















































































Liver TG, umol/g 6.4 0.7 7.1 0.7 12.4 0.9# 9.8 0.4# 
Values are mean  SEM for n = 6 per group; 1 = Taurine intake estimated based on daily 
water consumption; * = significantly different from all other groups, # = significantly 


















































































































Supplemental Figure 1. H&E Staining in Rats Provided a High Starch or High Sucrose Diet. 
(A) High starch diet (STD); (B) high starch diet with taurine in drinking water (STD + 
Taurine); (C) high sucrose diet (HSD); (D) high sucrose diet with taurine in drinking water 
(HSD + taurine). Data is representative of n=4-6 per group. 
 
Supplemental Figure 2. Western Blot Analysis in Rats Provided a High Starch or High 
Sucrose Diet. Representative western blots for GRP78, Chop, phosphorylated eIF2α, 
total eIF2α and actin.  STD,high starch diet for 4 wks; STD+T, high starch diet and 
drinking water with 2% (w/v) taurine for 4 wks; HSD, high sucrose diet for 4 weeks; 
HSD+T, high sucrose diet for 4 weeks and drinking water with 2% taurine (w/v). 
 
Supplemental Figure 3. Amelioration of Tunicamycin-Mediated Induction of the UPR in 
Mice by Taurine Supplementation. Liver sections were prepared from C57BL/6 mice four 
days after treatment with a single IP injection of either tunicamycin (0.5 mg/kg body 
weight) or PBS. Representative images are shown from each experimental group 
immunostained with (A), anti-KDEL and (B), anti-CHOP antibodies as described in the 























While there is potential for onion exudates as a therapeutic tool for NAFLD, 
many issues need to be addressed before this can happen.  Determining why the 
presence of bioactivity, specifically activity that influences insulin action and fat 
accumulation, is variable among batches is of utmost importance.  Possible sources of 
variability could include onion growth media inconsistencies, degradation of the 
relevant compounds, and/or calculation errors with regards to mass of lyophilized 
exudates.  Evaluation of the constituents of various media used to grow plants in the 
laboratory demonstrated a wide variability.  We have examined a few of these MS 
media (i.e. Caisson labs, Sigma, Phytotechnologies) and have observed that some of 
these media have effects on insulin-dependent phosphorylation of AKT.  It is also 
possible that these media will elicit a different composition of exudates upon interaction 
with the plant root.  Thus, a systemic study that evaluates onion root exudates grown 
under identical conditions but in different growth media is required. Degradation is 
another potential issue that could explain our variability in onion exudates bioactivity.  




4°C covered in foil and used within a month for the pilot in vivo study.  A second 
successful in vivo study was done using the same batch a few months later.  Thus, it was 
assumed that the bioactive compounds were stable.  It is possible that subsequent 
batches of exudates were less stable and were characterized by a loss of the relevant 
bioactive compounds.  Future studies would be handled in a way to minimize this risk by 
avoiding heat, light, and potentially oxidation.  Freezing samples post lyophilization at -
80°C and minimizing freeze/thaw cycling may help to preserve the bioactive compounds 
present.  After onion exudates were collected, they were sterile filtered and lyophilized 
to a powder; this powder contains a mixture of growth media components and 
compounds exuded by the plant roots.  This powder was then reconstituted in saline for 
intraperitoneal injections for in vivo studies, or in MEM growth media for in vitro 
studies.  The calculation for reconstitution was based on the mass of lyophilized onion 
exudates present; it is possible that mass measurements do not correlate with the 
amount of bioactive compounds present.  Also, post-lyophilization, the majority of mass 
comes from the 3% sucrose in the onion growth media; if any moisture remains mixed 
with the sucrose, the lyophilized onion exudates mass will not be accurate and could 
contribute to bioactive variability.   Ideally, removal of the sucrose would not only aid in 
mass measurements but also would prevent its interference in qualitative/quantitative 
HPLC screening of onion root exudates. 
 
Assuming the above issues and bioactivity variability can be eliminated, the next 




extractions and subsequent screening in liver cells or rats for bioactivity retention.  For 
example, a recent study performed an aqueous extraction of Belamcanda chinensis 
leaves followed by precipitation with 80% ethanol; the supernatant was freeze-dried, 
reconstituted in distilled water, and either further extracted with petroleum ether, 
chloroform, acetic ester, or n-butanol or eluted using a macroporous resin HPLC column 
and a gradient of water to 95% ethanol solvent, to isolate compound classes.1   These 
isolates were tested in male Wistar rats for hypoglycemic effects; isolates having the 
strongest hypoglycemic effects were further analyzed using NMR, MS, and UV spectral 
analysis and found to be isoflavones.1 Since onion root exudates show bioactivity both 
in vitro and in vivo, it would be much easier to test isolates in liver cells first, and then 
progress to rats for verification.   
 
It is not necessary to identify the exact compounds that are bioactive in onion 
root exudates in order to explore their bioactivities.  For example, crude bean root 
exudates were shown to promote germination of the insect pathogen Metarhizium 
anisopliae, in part through upregulation of genes involved in carbohydrate metabolism, 
lipid metabolism, cofactors and vitamins, energy metabolism, proteolysis, extracellular 
matrix/cell wall proteins, transport proteins, DNA synthesis, the sexual cycle and stress 
response.2  Extractions and isolations followed by bioactivity screening serve to further 
expand on the various physiologic roles of compound fractions. A study done on various 
Indian Ayurvedic medicinal plants found that three isopropanol extracts had potent 




prevention of starch breakdown.3 In the case of onion root exudates, once an isolate is 
determined to be maximally bioactive in terms of promoting insulin action and/or 
preventing fat accumulation, it can be used in order to determine potential details in its 
mechanism(s) of action.  As onion root exudates proved to have a potent stimulatory 
effect on pAKT, possible mechanisms of action could be through inhibition of protein 
tyrosine phosphatase 1β (PTP1β, involved in dephosphorylation of pAKT; liver-specific 
PTP1β knockout mice show improved hepatic insulin signaling4), proteaomal proteins 
involved in degradation of insulin signaling proteins (which has been shown to occur in 
adipocytes with proteosome inhibitors MG132 and lactacystin and led to prolonged 
insulin signaling and glucose transport5), or via stimulatory effects on upstream insulin 
signaling proteins or interactions. The ability of onion root exudates to prevent fatty 
acid-mediated hepatic lipid accumulation could be further examined in studies that 
directly investigated fatty acid transport and oxidation.   Giving liver cells and rats 
bioactive isolates of onion root exudates followed by genomic, proteomic and 
metabolomic analyses would provide a systems approach to showing global effects 
induced by the compounds of interest, either directly or indirectly.   
 
Once the above methods have been successfully implemented, they can be used 
to test other varieties of onion or related plant exudates for similar or more potent 
bioactivity towards NAFLD characteristics.  Much further down the road, methods to 
enrich the secretion or potency of the bioactive compounds in onion root exudates (or 




quality and quantity of root exudates;6 an example of this is a study involving induced 
biotic attack of the barley root system which resulted in root secretion of phenolic 
compounds with antimicrobial properties.7  If the target bioactive components of onion 
root exudates are phenolic and the barley and onion root systems are similar, perhaps a 
similar biotic induction would enrich the surrounding growth media.   
TAURINE 
As taurine has a diverse physiological role, determination of its mechanism of 
action in the context of treating or preventing NAFLD characteristics is the next step.  In 
our study, taurine reduced nutrient-(palmitate, high sucrose diet) and chemically-
(tunicamycin) induced hepatic steatosis, ER stress, inflammation and injury across four 
models of NAFLD. A high throughput method of analyzing gene expression, protein 
expression and interactions, and metabolic alterations induced by taurine would 
provide potential targets for further analysis.  Genomics, proteomics, and metabolomics 
are three exciting new areas of bioinformatics that could satisfy the need to look at 
multiple pathways and interactions to which taurine may directly or indirectly affect.  
Genomics utilizes vast arrays of cDNA probes that can be customized to desired genes or 
pathways.  As the resulting analysis produces an enormous amount of data, proper 
bioinformatics software is necessary in order to elucidate any significant findings.  
Proteomics involves gel separation of proteins followed by digestion, separation and 
identification using an LC/MS or variant of.  Proper software is, again, crucial since 
massive libraries must be used to piece together fragmented peptide sequences into the 




proteomics can also show protein interactions. Metabolomics uses LC/MS analysis of 
fluids such as plasma or urine in order to identify and quantify small molecules including 
metabolites.   
 
With respect to taurine treatment, one could envision looking at lipogenic, 
oxidative stress, ER stress, or inflammatory pathways and their respective signaling 
components to see what perturbations are induced.  Many studies have examined the 
antioxidant potential of taurine, however recently it has been implicated as having a 
role in calcium homeostasis in the brain, specifically through altering the presence of 
the calcium-binding proteins calbindin-D28k, calretinin, and parvalbumin, and reducing 
CaMKII activity.8 As calcium homeostasis is important in all cells, measuring taurine’s 
effect on calcium binding or signaling proteins in the liver may be a mechanism by which 
taurine reduces characteristics of NAFLD. Numerous studies have shown 
Tauroursodeoxycholate (TUDCA, a chemical chaperone that alleviates ER stress through 
enhanced protein folding) reduces hepatic steatosis, apoptosis, inflammation in 
adipocytes, hyperglycemia, and systemic insulin resistance in various experimental 
models.9-14 Taurine may act similarly, either through conjugation to form TUDCA or an 
active metabolite of TUDCA, and is thus a warranted mechanism to explore.  
Additionally, since taurine is endogenously made, one could look at differences in its 
amount at various stages of NAFLD to see if a deficiency could be a component to the 
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